Page last updated: 2024-08-23

raloxifene hydrochloride and Bone Loss, Perimenopausal

raloxifene hydrochloride has been researched along with Bone Loss, Perimenopausal in 561 studies

Research

Studies (561)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	76 (13.55)	18.2507
2000's	345 (61.50)	29.6817
2010's	117 (20.86)	24.3611
2020's	23 (4.10)	2.80

Authors

Authors	Studies
Chen, S; Gong, W; Lu, LL; Ma, HY; Zhang, AH	1
Hong, N; Kim, KJ; Lee, S; Rhee, Y; Shin, S	1
Baek, KH; Ha, J; Jeong, C; Kang, MI; Kim, J; Kim, MK; Kwon, HS; Lim, Y; Song, KH	1
Chung, YS; Lee, DY	1
Esmaily, H; Mehrnaz Aghili, S; Saeidi, S; Sahebari, M; Salari, M; Sarafraz Yazdi, M	1
Almutairi, M; Ashour, EA; Muhindo, D; Repka, MA	1
Adhikari, N; Bhattacharjee, M; Gupta, D; Pamnani, S; Panda, A; Rizvi, Z; Shehzad, S; Sijwali, PS; Sudhakar, R	1
Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M	1
Chang, CH; Tseng, TH; Wang, CH; Wang, ML; Yang, SJ; Young, TH	1
Fukunaga, M; Hagino, H; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Tanaka, S; Uemura, Y	1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T	1
Li, H; Li, X; Liu, S; Lu, S; Luo, M; Zhang, T	1
Deng, Y; Li, C; Li, L; Qu, Y; Wang, F	1
Ahmad, A; Ahmad, FJ; Farooq, U; Kohli, K; Mirza, MA; Mohapatra, S; Shakeel, F; Singh, D; Tripathi, A; Zakir, F	1
Fukunaga, M; Hagino, H; Miyazaki, T; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Sugimoto, T; Taguchi, A; Tanaka, S; Tsukiyama, M; Uemura, Y	1
Adikusuma, W; Chang, WC; Chou, PH; Chou, WH; Hung, KS; Lin, GH; Lu, HF; Mugiyanto, E; Wang, ST	1
Chang, J; Hong, S; Jeong, K; Lee, W	1
Chin, KY; Ima-Nirwana, S; Mohamad, NV	1
Goyal, R; Kumar, A; Saini, RV; Sharma, A; Sharma, L	1
Binkley, N; Borchardt, G; Goel, H; Krueger, D; Libber, J	1
Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N	1
Pinkerton, JV	1
Barry, MJ; Cooke, M; Denberg, TD; Fitterman, N; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; McLean, RM; Mir, TP; Qaseem, A; Schünemann, HJ	1
Hirata, M; Ichimaru, R; Inada, M; Matsumoto, C; Miyaura, C; Murphy, G; Nagase, H; Numabe, Y; Tominari, T; Watanabe, K; Yoshinouchi, S	1
Baidya, S; Barron, R; Fujiwara, S; Hamaya, E; Miyauchi, A; Nicholls, RJ; Pinto, L; Takada, J; Weston, A	1
Balasubramanian, A; Cooper, C; Cummings, SR; Feudjo, MT; Guo, H; Sprafka, JM; Watts, NB; Yusuf, AA; Zhou, J	1
Cho, DC; Gupta, R; Han, I; Kim, CH; Kim, KT; Kwon, JT; Lee, YS; Park, EK; Seo, YJ; Seu, SY; Sung, JK	1
Anthamatten, A; Parish, A	1
Conner, EA; Pinkerton, JV	1
Black, DM; Cheung, AM; Eastell, R; Murad, MH; Rosen, CJ; Shoback, D	1
Bei, MJ; Cao, XH; Dai, MW; Liu, N; Song, HP; Tian, FM; Wang, WY; Xiao, YP; Zhang, L; Zheng, ZY	1
Budoff, MJ	1
Amewou-Atisso, MG; Barrett-Connor, E; Collins, P; Daniels, LB; Grady, D; Mitlak, BH; Mosca, L; Wenger, NK	1
D'Amelio, P; Isaia, GC	1
Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J	1
Lopez-Picado, A; Mendoza-Edroso, C; Sánchez Garrido-Lestache, N	1
Amling, M; Beil, FT; Ignatius, A; Jeschke, A; Khadem, S; Marshall, RP; Pogoda, P; Spiro, AS	1
Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S	1
Chines, AA; Gallagher, JC; Mirkin, S; Shi, H	1
Eastell, R; Finigan, J; Naylor, K; Paggiosi, MA; Peel, NF	1
Gallagher, JC; Tella, SH	1
Gallo-Padilla, D; Gallo-Vallejo, JL	1
Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U	1
Lin, SJ; Lin, TC; Yang, CY; Yang, YH	1
Dalkin, AC; Pinkerton, JV; Thomas, S	1
Kanis, JA; Kim, K; Luo, X; Sutradhar, S; Svedbom, A	1
Diab, DL; Watts, NB	1
Alam, J; Burge, R; Gold, DT; Naegeli, AN; Shen, W; Shih, T; Silverman, S	1
Hamaya, E; Sowa, H	1
Urushihara, H	1
Pinkerton, JV; Thomas, S	1
Silverman, S	1
Marc, J; Mencej-Bedrač, S; Mlakar, SJ; Preželj, J; Zavratnik, A; Zupan, J	1
Fahrleitner-Pammer, A; Haschka, J; Kapiotis, S; Kocijan, R; Muschitz, C; Pavo, I; Resch, H; Schima, W	1
Ali, J; Ali, MM; Baboota, S; Fazil, M; Saini, D	1
Castro-Santana, LE; Díaz-Correa, LM; Ramírez-García, LM; Vilá, LM	1
Abdelazim, IA; Abdelrazak, KM; Al-Kadi, M; Faza, MA; Nusair, BM; Yehia, AH	1
Fogelman, I; Hampson, G; Ishtiaq, S	1
Hamaya, E; Ohta, H; Sowa, H; Taketsuna, M	1
Farbodara, T; Haghverdi, F; Mortaji, S; Saidi, N; Soltani, P	1
Burge, R; Flynn, JA; Fujiwara, S; Graham-Clarke, P; Hamaya, E; Sato, M	1
Hamaya, E; Taketsuna, M; Tanaka, K; Urushihara, H; Yoh, K	1
Hirai, K; Inoue, T; Kanehara, H; Nagatoya, K; Nishimoto, K; Okada, S; Shibahara, N; Takahashi, T; Ueda, H; Ueno, N; Yasuda, H	1
Hamaya, E; Sowa, H; Taketsuna, M; Takeuchi, Y	1
Choi, NK; Kim, J; Lee, J; Park, BJ; Shin, JY; Song, HJ	1
Chen, YC; Cheng, TT; Lin, WC; Lui, CC; Su, FM	1
Chaki, O	1
Eastell, R; Gossiel, F; Jacques, RM; Naylor, KE; Peel, NF	1
Arias, L; Komm, BS; Mirkin, S; Palacios, S; Pan, K; Williams, R	1
Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L	1
Payer, J; Rosa, J; Svobodník, A; Vanuga, P	1
Chao, HT; Cheng, MH; Lee, WL; Wang, PH	1
Jordan, VC	8
Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK	1
Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L	1
Alonso, G; de la Higuera, M; Escobar-Jiménez, F; Fernández-García, D; Luna, JD; Mezquita-Raya, P; Muñoz-Torres, M; Ochoa, AS; Reyes-García, R; Ruiz-Requena, ME	1
Cano, A; Hermenegildo, C; Novella, S; Oviedo, PJ; Tarín, JJ	1
Biri, A; Bozkurt, N; Ciftci, B; Guner, H; Ilhan, MN; Korucuoglu, U	1
Clifford, T; Johnson, NK; Smith, KM	1
Hanai, Y; Kozawa, O; Matsushima-Nishiwaki, R; Minamitani, C; Otuka, T; Takai, S; Tokuda, H	1
Keating, GM; Moen, MD	1
Ohta, H	3
Verhaar, HJ	1
Foley, KA; Foster, SA; Johnston, JA; Long, SR; Meadows, ES; Pohl, GM; Wang, S	1
Stepan, JJ; Zikan, V	1
Bobula, J; Lips, P; van Schoor, NM; Yu, H	1
Vogel, VG	2
Adachi, S; Harada, A; Kozawa, O; Matsushima-Nishiwaki, R; Minamitani, C; Mizutani, J; Natsume, H; Otsuka, T; Tokuda, H	1
Bogataj, M; Marc, J; Mrhar, A; Trontelj, J; Zavratnik, A	1
Cegieła, U; Folwarczna, J; Kaczmarczyk-Sedlak, I; Nowińska, B; Pytlik, M; Sliwiński, L; Trzeciak, H; Trzeciak, HI	1
Bouxsein, ML; Chen, P; Delmas, PD; Glass, EV; Kallmes, DF; Mitlak, BH	1
Barrett-Connor, E; Cox, DA; Grady, D; Mitlak, B; Mosca, L; Song, J	1
Cosman, F; Glass, EV; Krege, JH; Mauck, KF; Recknor, C; Wermers, RA; Xie, L	1
Constantine, G; Gallagher, JC; Kagan, R; Lindsay, R; Pickar, JH	1
Ohnaka, K; Takayanagi, R	1
Gorai, I; Hattori, S; Iwaoki, Y; Tanaka, Y	2
Ahmet-Camcioglu, N; Durmus-Altun, G; Ekuklu, G; Kucuk, M; Okman-Kilic, T	1
Cox, DA; Downs, RW; Dowsett, SA; Ghosh, A; Harper, K; Moffett, AM	1
Lewiecki, EM	1
Emmelot-Vonk, MH; Jacobsen, DE; Samson, MM; Verhaar, HJ	1
Eriguchi, R; Miura, S; Sato, Y; Umakoshi, J	1
Domeki, N; Ikeda, S; Kasai, K; Kawagoe, Y; Matsumura, M; Monden, T; Nakatani, Y; Shimizu, H; Yanagi, K	1
Ichikawa, S; Kanda, T; Kasama, S; Kumakura, H; Kurabayashi, M; Murakami, M; Sumino, H; Takahashi, T; Takayama, Y	1
Howard, E; Tagliarino-Jones, H	1
Fujii, Y; Fujita, T; Munezane, H; Ohue, M; Takagi, Y	1
Becker, C	1
Nakamura, T; Sakai, A	1
Inoue, D	1
Iba, K; Takada, J; Yamashita, T; Yoshizaki, T	2
Iwamoto, J	1
Gorai, I; Hori, H	1
Hasegawa, M; Ichimura, S; Satomi, K	1
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P	1
Miyakoshi, N	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Barker, C; Brixen, K; del Pino, J; Farrerons, J; Keen, R; Lyritis, G; Marin, F; Nickelsen, TN; Pfeifer, M	1
Brixen, KT; Langdahl, BL; Nielsen, DS; Sørensen, HA; Sørensen, OH	1
Brown, PH; Hortobagyi, GN	1
Brookhart, MA; Cadarette, SM; Katz, JN; Patrick, AR; Solomon, DH	1
Adachi, JD; Brown, JP; Chesnut, CH; Chines, AA; Christiansen, C; Constantine, GD; Fernandes, CE; Kung, AW; Levine, AB; Palacios, S	1
Glendenning, P; Inderjeeth, CA; Lee, S	1
Cochet, T; Cohade, C; Pouillès, JM; Ribot, C; Trémollieres, F	1
Borgström, F; Burge, RT; Ivergård, M; Kanis, J; Ström, O; Tosteson, AN	1
Berthelot, JM; Glémarec, J; Guillot, P; Le Goff, B; Maugars, Y	1
Eastell, R; Krege, JH; Ni, X; Rogers, A	1
Brandi, ML	1
Arnsten, JH; Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Melamed, ML; Neugarten, J; Silbiger, SR	1
Hadji, P; Kyvernitakis, I; Seker-Pektas, B; Wetzel, K; Ziller, V	1
Akiyoshi, M; Kato, K; Kubota, T; Obayashi, S; Terauchi, M	1
Giner, M; Miranda, C; Montoya, MJ; Pérez-Cano, R; Rios, MJ; Vázquez, MA	1
Schmidt, C	1
Archer, DF	1
Ho, LY; Lee, HK; Ma, KM; Mok, CC; To, CH; Ying, KY; Yu, KL	1
Thiebaud, D	1
Desouky, B; Ellakwa, H; Sanad, Z	1
Bachmann, G; Constantine, GD; Crosby, U; Feldman, RA; Ronkin, S	1
Jordan, VC; Ko, SS	1
Alam, J; Cox, DA; Dowsett, SA; Kendler, DL; Palacios, S; Stock, J; Zanchetta, J	1
Carlsten, H; Engdahl, C; Erlandsson, M; Holmdahl, R; Islander, U; Jochems, C; Lagerquist, M; Nandakumar, KS; Ohlsson, C	1
Fukagawa, M; Itoh, K; Kawanishi, H; Matsushita, K; Moriishi, M; Tanaka, M	1
D'Amelio, P; D'Amico, L; Ferracini, R; Isaia, GC; Patanè, S; Pescarmona, GP; Ravazzoli, M; Roato, I; Sassi, F; Tamone, C; Veneziano, L	1
Lello, S	1
Chung, YE; Kim, GS; Kim, HH; Kim, SY; Koh, JM; Lee, SH; Lee, SK; Lee, SY; Lorenzo, JA; Mirza, FS	1
Jacobsen, DE; Melis, RJ; Olde Rikkert, MG; Verhaar, HJ	1
Dubois, M; Marakovits, KA; O'Sullivan, DM; Schnatz, PF	1
Krege, JH; Mitlak, BH; Ni, X; Recker, RR	1
Owens, G	1
Bhat, KM; Nampurath, GK; Potu, BK; Rao, MS	1
Gitlin, M; Jick, S; Li, L; Roddam, A; Shearer, A; Shepherd, S; Taylor, A	1
Jouyama, K; Matoba, K; Mokuda, S; Okuda, Y; Onishi, M; Sawada, N; Takasugi, K; Yamada, A	1
Alonso-Garcia, G; Fernández-García, D; Mezquita-Raya, P; Muñoz-Torres, M; Reyes-García, R; Rozas-Moreno, P; Sebastián-Ochoa, A	1
Alam, J; Bhattoa, HP; Cox, DA; Dowsett, SA; Goldstein, SR; Muram, D; Neven, P; Sipos, A	1
Cano, A; García-Pérez, MÁ; Hermenegildo, C; Pineda, B; Tarín, JJ	1
Abbas-Chorfa, F; Ambrosi, V; Caillet, P; Chapurlat, R; Jaglal, SB; Reymondier, A; Schott, AM	1
Birkhäuser, M; Buchard, PA; De Geyter, C; Imthurn, B; Lamy, O; Lippuner, K; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P	1
Goto, W; Hamaya, E; Iikuni, N; Miyauchi, A; Nihojima, S; Sowa, H; Taketsuna, M; Yokoyama, S	1
Hadji, P	1
Jerums, G; MacIsaac, RJ; Seeman, E; Varadarajan, S; Vu, TD	1
Chen, CH; Chen, JC; Cheng, YM; Fu, YC; Hsieh, CH; Huang, HT; Huang, PJ; Kang, L; Lin, SY	1
Hamaya, E; Iikuni, N; Miyauchi, A; Sowa, H; Taketsuna, M; Tanaka, K; Urushihara, H; Yamamoto, T; Yoh, K	1
Ben Sedrine, W; Hiligsmann, M; Reginster, JY	1
Cosman, F; Keaveny, TM; Kopperdahl, D; Krege, JH; Krohn, KD; Wan, X; Wermers, RA	1
Ando, H; Fujimura, A; Hosohata, K; Inano, A; Kaneko, S; Matsushita, E; Nagai, Y; Ookami, H; Otoda, T; Saito, T; Takamura, T; Ushijima, K	1
Gluck, O; Maricic, M	3
Pouillès, JM; Ribot, C; Trémollières, F	1
Adachi, JD; Black, DM; Delmas, PD; Eastell, R; Ensrud, KE; Genant, HK; Gennari, C; Harper, KD; Harris, ST; Pols, HA; Recker, RR; Reginster, JY; Sarkar, S; Wu, W	1
Flik, KR; Gardner, MJ; Lane, JM; Mooar, P	1
Adachi, J; Cranney, A; Guyatt, G; Robinson, V; Shea, B; Tugwell, P; Weaver, B; Wells, G; Zytaruk, N	1
Nagykálnai, T	1
Arangino, S; Cagnacci, A; Ibba, G; Melis, GB; Orrù, M; Paoletti, AM; Volpe, A; Zanni, A	1
Cox, DA; Hurn, PD; Littleton-Kearney, MT; Ostrowski, NL; Rossberg, MI	1
Lopes, P; Trémollières, F	1
Basile, G; Cannavò, S; Frisina, N; Gaudio, A; Lasco, A; Morabito, N; Nicita-Mauro, V	1
Chmel, R; Rob, L; Strnad, P	1
Adachi, JD; Crans, GG; Fuerst, T; Genant, HK; Harper, KD; Lu, Y; Siris, E; Wong, M	1
Gustafson, Y; Johansson, A; Littbrand, H; Nordström, P; Von Heideken Wågert, P	1
Baranauskaite, A; Savickiene, A	1
Romero, M	1
Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W	1
Celi, M; D'Erasmo, E; Letizia, C; Mazzuoli, GF; Minisola, S; Ragno, A	1
Mossetti, G; Nappi, C; Numis, FG; Nunziata, V; Palomba, S; Rendina, D; Russo, T; Vuotto, P; Zullo, F	1
Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W	1
Cauley, JA; Ewing, S; Modugno, F; Ness, RB	1
Hartmann, LC; Riggs, BL	1
Arangino, S; Cagnacci, A; Renzi, A; Volpe, A; Zanni, AL	1
Forsmo, S; Skolbekken, JA	1
Bartl, R	1
Benedetti-Panici, P; Cano, A; de Villiers, T; Hillard, T; Lunde, T; Marinescu, B; Neven, P; Nickelsen, T; Peer, E; Quail, D; Tiitinen, A	1
Delmas, PD; Fontana, A	2
Cagnacci, A; Volpe, A; Zanni, AL	1
Reincke, M	1
Laupacis, A	1
Yendt, ER	1
Felsenberg, D; Glüer, CC; Mühlenbacher, D; Nickelsen, T; Pavo, I; Payer, J; Quail, D; Reginster, JY; Resch, H; Schmitt, H; Stepan, J	1
Anderson, PW; Barrett-Connor, E; Ensrud, KE; Harper, K; Krueger, KA; Mason, TM; Sashegyi, A	1
Reid, IR	1
Fukunaga, M; Harper, K; Itabashi, A; Morii, H; Nakamura, T; Ohashi, Y; Sarkar, S; Taketani, Y	1
Bajaj, S; Saag, KG	1
Black, DM; Downs, RW; Fuerst, T; Johnell, O; Kanis, JA; Pavo, I; Sarkar, S; Secrest, RJ	1
Lippuner, K	1
Lakatos, P	1
Calcagnile, F; Carlo Isaia, G; Cosentino, L; D'Amelio, P; Muratore, M; Quarta, E; Tamone, C; Tinelli, F	1
Adachi, JD; Crans, GG; Delmas, PD; Genant, HK; Siris, E; Stock, JL; Wong, M	1
Draper, MW	1
Keck, E	1
Ish-Shalom, S; Segal, E; Tamir, A	1
Loza, E	1
Guyot, B; This, P	1
Agnusdei, D; Bruyere, O; Collette, J; Henrotin, Y; Reginster, JY; Sarkar, S; Zegels, B	1
Kessenich, C	1
Clowes, JA; Eastell, R; Peel, NF	1
Hatzigeorgiou, C; Jackson, JL; Tofferi, JK; Wei, GS	1
Rollins, G	1
Itabashi, A	2
Acebes, JC; Graña, J; Herrero-Beaumont, G; Marín, F; Miguélez, R; Sacristán, J; Torrijos, A; Turbí, C	1
Ferrer-Barriendos, J; Gaines, K; Geusens, P; Melton, ME; Ribot, C; Sambrook, PN; Solimano, JA; Verbruggen, N	1
Braddon, J; Phillips, P	1
Xu, L	1
Chen, XP; Diez-Perez, A; Ekangaki, A; Harpe, K; Huang, QR; Li, HL; Liu, H; Liu, JL; Liu, YJ; Lu, JH; Qin, YJ; Wei, DL; Zhang, Y; Zhang, ZL; Zheng, YM; Zhu, HM	1
Krieg, MA; Lamy, O	1
Crans, G; Ettinger, B; Pavo, I; San Martin, J	1
Balogh, A; Black, DM; Johnell, O; Kanis, JA; Pavo, I; Poor, G; Sarkar, S; Zhou, C	1
Franzson, L; Hansdóttir, H; Prestwood, K; Sigurdsson, G	1
Korsić, M	1
Alenfeld, F; Boivin, G; Feyen, JH; Lakatos, P; Stepan, JJ	1
László, A	1
Albertazzi, P; Missiroli, N; Natale, V; Pedrini, D; Salgarello, M	1
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A	1
Chen, XP; Diez-Perez, A; Ekangaki, A; Harper, K; Huang, QR; Li, HL; Liu, H; Liu, JL; Liu, YJ; Lu, JH; Qin, YJ; Wei, DL; Zhang, Y; Zhang, ZL; Zheng, YM; Zhu, HM	1
Cianci, A; De Leo, V; Farina, M; La Marca, A; Morgante, G; Petraglia, F	1
Almeida, MJ; Farias, ML; Gomez, G; Kayath, MJ; Luebbert, H; Mönnig, E; Nickelsen, T; Palacios, S; Quail, DC; Turbi, C; Yabur, JA	1
Clarke, A; Layton, D; Shakir, SA; Wilton, LV	1
Barrett-Connor, E; Blackwell, T; Davidowitz, N; Kanaya, AM; Krueger, K; Yaffe, K	1
Delmas, PD; Kulkarni, PM; Plouffe, L; Silverman, SL; Stock, JL; Wong, M	1
Ciaccia, A; Cummings, S; Ettinger, B; Grady, D; Moscarelli, E; Plouffe, L; Sarkar, S	1
Cauley, JA; Johnell, O; Kulkarni, PM; Stock, JL; Wong, M	1
Del Puente, A; Esposito, A; Lello, S; Migliaccio, S; Ott, SM	1
Zizic, TM	1
Keller, MI	1
Diez-Perez, A; Fuerst, T; Genant, HK; Lang, T; Pinette, KV; Thiebaud, D; Zhou, C	1
Vlak, T	1
Ewing, S; Lips, P; Oleksik, AM; Shen, W; van Schoor, NM	1
Barrett-Connor, E; Cauley, JA; Cummings, SR; Disch, D; Martino, S; Mershon, J; Powles, TJ; Secrest, RJ	1
Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A	1
Mori, S	1
Inaba, M	1
Nozaki, M	2
Cyaki, O	1
Kurebayashi, J	1
Honjo, H	1
Higuchi, T; Mizunuma, H	1
Sohen, S	1
Shintani, M	1
Hagino, H	1
Aglianò, AM; Agnusdei, D; Ammendola, S; Brama, M; Gazzaniga, P; Gianni, W; Marigliano, V; Migliaccio, S; Patanè, F; Pietropaolo, M; Ricci, A; Scandurra, R; Spera, G; Votano, S	1
Borgström, F; Johnell, O; Jönsson, B; Kanis, JA; Oden, A; Sykes, D	1
Bradbury, J	1
Angulo, P; Harnois, DM; Jorgensen, R; Levy, C; Lindor, KD	1
Hamaya, E; Kobayashi, H	1
Falbo, A; Lombardi, G; Manguso, F; Mastrantonio, P; Nunziata, V; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F	1
Brixen, K; Mosekilde, L; Vestergaard, P	1
Blackwell, T; Cummings, SR; Ensrud, K; Grady, D; Henderson, VW; Krueger, K; Sarkar, S; Yaffe, K	1
Urano, T	2
Altan, M; Buyukcelik, A; Dogan, M; Doruk, H; Utkan, G; Yalcin, B; Yalcin, S	1
Damilakis, J; Hadjipavlou, A; Katonis, P; Papadokostakis, G	1
de Los Angeles, MM; Goldberg, GL; Goldman, NA; Jones, JG	1
Barrett-Connor, E; Keech, CA; Sashegyi, A	1
Gaudio, A; Morabito, N	1
Cheung, AM; Grady, D; Litwack, S; Walsh, JM; Yang, D	1
Bontis, J; Dinas, K; Tsalikis, T; Zafrakas, M; Zepiridis, L	1
Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M	1
Bjarnason, NH	1
Diehr, S; Mijal, S; Nashelsky, J	1
Hosking, DJ; Pande, I	1
Adachi, JD; Cranney, A	1
Adachi, JD; Adami, S; Kulkarni, PM; Stock, JL; Wong, M	1
Cummings, SR; Diez-Perez, A; Eastell, R; Goemaere, S; Harris, ST; Kulkarni, PM; Qu, Y; Siddhanti, SR; Siris, ES; Song, J; Stock, JL; Wong, M; Zanchetta, JR	1
Carreras, R; Checa, MA; Conangla, M; Garrido, A; Prat, M; Rueda, C	1
Baytan, S; Bozkaya, H; Eminagaoglu, S; Karahan, SC; Ozeren, M; Ozgur, M; Unsal, M	1
Disch, D; Dowsett, SA; Keech, CA; Martino, S; Mershon, JL	1
Crans, GG; Delmas, PD; Diez-Perez, A; Pinette, KV; Seeman, E	1
Cantor, P; Deal, C; Eriksen, EF; Glass, EV; Krege, JH; Myers, SL; Omizo, M; Schwartz, EN; Wang, J	1
Brown, SA; Rosen, CJ	1
Fujinaga, M; Matsuo, K; Nakamoto, M; Tsuchiya, K; Yasunaga, C	1
Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB	1
Sambrook, P	1
Basson, BR; Michalská, D; Pavo, I; Stepan, JJ	1
Azevedo, GD; Baggio, MS; Franco, RF; Maranhão, TM; Sá, MF	1
Qu, Y; Stock, JL; Thiebaud, D; Wong, M	1
Beck, TJ; Crans, GG; Daphtary, MM; Desaiah, D; Harper, KD; Semanick, LM; Uusi-Rasi, K	1
Reginster, JY; Sarlet, N	1
Badia, X; Ferrer, J; Fuentes, M; Grifols, M; Guilera, M	1
Barrett-Connor, E; Cox, DA; Dowsett, SA; Ensrud, K; Geiger, MJ; Genazzani, AR; McNabb, M	1
Devogelaer, JP; Reginster, JY	1
Ribot, C; Trémollières, F	1
Asano, A; Kobayashi, J; Mabuchi, H; Muramoto, H; Murase, Y; Yamaaki, N; Yonezawa, K	1
Gilchrist, N	1
Boscaro, M; Francucci, CM; Romagni, P	1
He, JW; Hu, YQ; Huang, QR; Li, M; Liu, YJ; Qin, YJ; Zhang, ZL	1
Akercan, F; Bilgen, I; Cirpan, T; Gundem, G; Itil, IM; Yucebilgin, MS	1
de Vernejoul, MC	1
Baris, N; Gol, M; Guneri, S; Posaci, C	1
Kastelan, D; Korsić, M	1
Audran, M; Chappard, D; Hoppé, E; Legrand, E	1
Hochberg, MC; Rizzoli, R	1
Allerheiligen, SR; Callies, S; Forgue, ST; Ni, L; Peck, R; Sinha, V; Zhang, L	1
Dayspring, T; Keech, C; Qu, Y	1
Cafiero, A; Cobellis, L; Mainini, G; Messalli, EM; Ragucci, A; Salzillo, PL; Scaffa, C	1
DeGregorio, M; Erkkola, R; Halonen, K; Heikkinen, J; Komi, J; Lammintausta, R; Lankinen, KS; Saarikoski, S; Tuppurainen, M; Väänänen, K; Ylikorkala, O	1
Miki, T; Tamura, A	1
Fassbender, WJ; Kurth, A; Stumpf, UC	1
Adachi, J; Blackhouse, G; Goeree, R	1
De Leo, V; Delia, A; Morgante, G; Musacchio, MC; Petraglia, F; Severi, FM	1
Kleerekoper, M	3
Hamaya, E; Huang, QR; Liu, JL; Morii, H; Nakamura, T; Qu, Y; Thiebaud, D; Zhu, HM	1
Aricioğlu, A; Biri, A; Ciftçi, B; Gülbahar, O; Gürsoy, R; Korucuoğlu, U; Nas, T	1
Cauley, JA; Cummings, SR; Disch, DP; Dowsett, SA; Lippman, ME; Martino, S; Mershon, JL	1
Matsumoto, T	1
Kim, SH; Oh, JM; Shin, HT; Shin, WG; Song, EK; Yeom, JH	1
Aytürk, S; Berberoglu, Z; Demirag, NG; Ertugrul, DT; Gürsoy, A; Pamuk, B; Sahin, M; Tutuncu, NB; Unal, AD; Yücel, M	1
Roux, C	1
Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I	1
Cauley, JA; Cummings, SR; Dowsett, SA; Mershon, JL; Song, J	1
Levo, Y; Pines, A	1
Cremers, S; Garnero, P	1
Biberoglu, K; Biri, A; Ciftci, B; Ergun, MA; Gursoy, R; Ilhan, MN; Korucuoğlu, U; Yurtcu, E	1
Cauley, JA; Gaich, CL; Kendler, D; Kulkarni, PM; Lewiecki, EM; Lorraine, J; Plouffe, L; Qu, Y; Recker, RR; Recknor, CP; Rooney, TW; Stock, JL; Utian, WH; Wong, M	1
Minshall, ME; Moses, KH; Shen, W; Silverman, SL; Xie, S	1
Fadillioglu, E; Kaya, H; Ozgocmen, S; Yilmaz, Z	1
Goldstein, SR	2
Helsberg, K; Kessler, F; Langer, F; Nickelsen, T; Oertel, H; Scharla, S	1
Gold, DT; Silverman, SL	1
Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D	1
Esinler, I; Haberal, NA; Kuscu, E; Oktem, M; Zeyneloglu, HB	1
Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH	1
Dhungana, B; Dowsett, SA; Feng, M; Hodis, HN; Keech, CA; Li, Y; Mack, WJ	1
Agostinelli, D; de Terlizzi, F	1
Ando, H; Kaneko, S; Komura, T; Matsushita, E; Minato, H; Shimizu, A; Takamura, T; Zen, Y	1
Albertazzi, P; Bottazzi, M; Sharma, S	1
Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T	1
Blankenstein, MA; Bravenboer, N; Holzmann, PJ; Lips, P; van Essen, HW	1
Hosoi, T	1
Aydin, K; Guclu, F; Hekimsoy, Z; Kafesciler, SO; Kirmaz, C; Ozmen, B	1
Byrjalsen, I; Christiansen, C; Karsdal, MA; Leeming, DJ; Qvist, P	1
Rizzoli, R	1
Carlsten, H; Islander, U; Jochems, C; Kallkopf, A; Lagerquist, M; Ohlsson, C	1
Fukao, A; Komatsu, Y; Majima, T; Matsumura, T; Nakao, K; Ninomiya, K; Satoh, N; Shimatsu, A	4
Barbuto, N; Cosman, F; Lindsay, R; Nieves, JW; Zion, M	1
Adami, S; Brandi, ML; Brown, JP; Dalsky, GP; Econs, MJ; Felsenberg, D; McClung, M; Muñoz-Torres, M; San Martin, J; Sipos, A; Xie, L	1
Deswaef, A; Fabri, V; Mertens, R; Rabenda, V; Reginster, JY; Sumkay, F; Vannecke, C; Vanoverloop, J; Verpooten, GA	1
Takeuchi, Y	1
Mizunuma, H	1
Okazaki, R	1
Okano, H	1
Burshell, AL; Cauley, JA; Delmas, PD; Dowsett, SA; Mershon, JL; Secrest, RJ; Song, J	1
Adami, S; Davis, SR; Delmas, PD; Hensen, J; Nijland, EA; van Os, S	1
Adomaityte, J; Farooq, M; Qayyum, R	1
Eiken, PA	1
Cosman, F; Glass, EV; Krege, JH; Recknor, CP; Wermers, RA; Xie, L	1
Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L	1
Mashiba, T	1
Colin, C; Couris, CM; Huot, L; Jaglal, S; Schott, AM; Tainturier, V	1
de Oliveira, ML; Delmanto, A; Fernandes, CE; Nahas, EA; Nahas-Neto, J; Traiman, P	1
Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Jamal, SA	1
Carlsten, H; Håkansson, C; Jochems, C; Lagerquist, M; Ohlsson, C	1
Gärtner, R	1
Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T	1
Atar, I; Kuscu, E; Muderrisoglu, H; Oktem, M; Yildirir, A; Zeyneloglu, HB	1
Hansdóttir, H	1
Bryant, HU; Kim, J; Magee, D; McClintock, C; Sato, M; Slemenda, CW; Turner, CH	1
Arnaud, C; Draper, MW; Flowers, DE; Harper, KD; Huster, WJ; Neild, JA	1
Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE	1
Raisz, LG	1
Gradishar, WJ; Jordan, VC	1
Bryant, HU; Cox, MB; Draper, MW; Hol, T	1
Bjarnason, NH; Christiansen, C; Delmas, PD; Draper, M; Huster, WJ; Mitlak, BH; Ravoux, AC; Shah, AS	1
Bryant, HU; Dere, WH	1
Powles, TJ	1
Bush, TL; Cole, RC; Flaws, JA	1
Friedman, MN	1
Nelson, NJ	1
Runowicz, C	1
Rossi, G	1
Zaidi, M	1
Dere, WH	1
Broy, S; Civitelli, R; Fleischmann, R; Gagel, R; Khosla, S; Lucas, M; Lukert, B; Maricic, M; Miller, P; Pacifici, R; Recker, R; Sarran, HS; Short, B; Short, MJ	1
Meier, CA	1
Cohen, FJ; Eckert, S; Mitlak, BH	1
Tonino, RP	1
Kupecz, D	1
Anderson, PW; Barrett-Connor, E; Collins, P; Cox, DA; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Wenger, NK	1
Argueta, R; Caplan, RH; Knickerbocker, RK; Lufkin, EG; Nickelsen, T; Riggs, BL; Whitaker, MD	1
Robb-Nicholson, C	1
Heufelder, AE; Hofbauer, LC	1
Khovidhunkit, W; Shoback, DM	1
Cox, DA; Crook, TH; Lufkin, EG; Nickelsen, T; Riggs, BL	1
McClung, BL	1
Brockie, J	1
Evans, MF; Park, L	1
Nishizawa, Y; Shioi, A	1
Bjarnason, NH; Black, D; Cauley, JA; Costa, A; Cummings, SR; Eckert, S; Glusman, JE; Grady, D; Jordan, VC; Krueger, KA; Lippman, ME; Morrow, M; Nickelsen, T; Norton, L; Powles, TJ	1
Fitzpatrick, LA	1
Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB	1
Ullom-Minnich, P	1
Agnusdei, D	1
Watts, NB	2
MacReady, N	1
Rubin, CD	1
Hart, W; Netelenbos, JC	1
Da Camara, CC; Early, JE; Scott, JA	1
Avioli, LV; Black, DM; Christiansen, C; Cohen, FJ; Cummings, SR; Delmas, PD; Eckert, S; Ensrud, KE; Ettinger, B; Genant, HK; Glüer, CC; Knickerbocker, RK; Krueger, K; Lips, P; Mitlak, BH; Nickelsen, T; Stakkestad, J; Zanchetta, JR	1
McClung, MR	1
Agnusdei, D; Augendre-Ferrante, B; Liu-Léage, S	1
Christiansen, C	1
Faglia, G	1
Agnusdei, D; Iori, N	1
Lindsay, R	1
Compston, J	2
Feinberg, AW	1
Chapman, B	1
Gass, ML	1
Kleiverda, G	1
Boyce, EG; Parks, SM; Rinaldi, C; Umland, EM	1
Arnaud, CD; Chiu, KM; Roe, EB	1
Burckhardt, P	1
Gaspard, UJ; Kalbus, MF; van den Brûle, FA	1
Meunier, PJ; Vignot, E	1
Miller, JL	1
Cohen, FJ; Lu, Y	1
Confavreux, E; Draper, MW; Garnero, P; Liu, T; Liu-Leage, S; Meunier, PJ; Paris, E; Sarkar, S; Vignot, E; Wong, M	1
Jurida, N; Pávó, I; Szúcs, J	1
Black, D; Blackwell, T; Browner, W; Cummings, SR; Eckert, S; Marcus, R; Palermo, L; Pearson, J; Wallace, R	1
Baran, DT	1
Cefalu, CA	1
Body, JJ; Sternon, J	1
Ito, M; Miyaura, C; Nozawa, S; Ohta, H; Onoe, Y; Suda, T	1
von Holst, T	1
Becker-Brüser, W; Halbekath, J; Wille, H	1
Delmas, PD	2
Ciaponi, M; Gambacciani, M	1
Bravenboer, N; Compston, J; Lips, P; Oleksik, A; Ott, SM; Vedi, S	1
Cooper, C; Dawson, A; Kanis, J; Lips, P; Minshall, ME; Oleksik, A; Shen, W	1
Bashore, R	1
Mincey, BA; Moraghan, TJ; Perez, EA	1
O'Regan, RM	1
Karch, AM; Karch, FE	1
Clemett, D; Spencer, CM	1
Cox, DA; Heath, H; Plouffe, L	1
Rosenfeld, JA	1
Malinowski, JM; Snyder, KR; Sparano, N	1
Depree, P	1
Dijkmans, BA; Lems, WF	1
Birkhäuser, MH	1
Chapurlat, R; Delmas, PD	1
Compston, JE	1
Eckert, S; Freedman, M; Lippman, ME; Lo, SC; O'Gorman, J; San Martin, J; Walls, EL; Zeng, J	1
Bogado, CE; Zanchetta, JR	1
Chylova, K; Fedelesova, V	1
Delmas, PD; Eastell, R; Garnero, P; Seibel, MJ; Stepan, J	1
Grossman, LD	1
Black, D; Cox, D; Cummings, S; Duong, T; Lips, P; Nickelsen, T; Oleksik, A	1
Dardes, RC; Jordan, VC	1
Cauley, JA; Costa, A; Eckert, S; Farrerons, J; Jordan, VC; Karasik, A; Krueger, KA; Lippman, ME; Mellstrom, D; Morrow, M; Muchmore, DB; Ng, KW; Norton, L; Powles, TJ; Purdie, DW; Schmitt, H; Silfen, SL; Ste-Marie, LG; Stepan, JJ; Walls, EL	1
Gray, K	1
Deal, C; Lufkin, EG; Wong, M	1
Hoon, TS; Leok, GC; Yosipovitch, G	1
Lenchik, L; Watts, NB	1
Barrett-Connor, E; Cox, DA; Grady, D; Krueger, K; Nickelsen, T; Sarkar, S; Yaffe, K	1
Altavilla, D; Arcoraci, V; Cancellieri, F; Corrado, F; Cucinotte, D; D'Anna, R; Frisina, N; Minutoli, L; Morabito, N; Saitta, A; Squadrito, F; Squadrito, G	1
Asma, G; Duong, T; Lips, P; Oleksik, A; Pliester, N; Popp-Snijders, C	1
Ham, H; Rozenberg, S	1
Asma, G; Duong, T; Lips, P; Oleksik, AM; Pliester, N; Popp-Snijders, C	1
Slagle, MA	1
Ettinger, B; Forsyth, B; Pressman, A; Tosteson, AN	1
Wade, JP	1
Neven, P; Vergote, I	1
Chan, HW	1
Patlak, M	1
Pfeilschifter, J	3
Duntas, LH; Koutras, DA; Mantzou, E	1
Anderson, PW; Barrett-Connor, E; Collins, P; Grady, D; Helterbrand, JD; Kornitzer, M; Mosca, L; Moscarelli, E; Paul, S; Wenger, NK; Wright, TJ	1
Harper, KD; Minshall, ME; Shen, W; Silverman, SL; Xie, S	1
Evans, MF; Hathirat, S	1
Crandall, C	1
Beitz, J; Brinker, A	1
Black, DM; Harper, KD; Mitlak, BH; Sarkar, S; Stock, JL; Wong, M	1
Melton, LJ; Riggs, BL	1
Cauley, JA; Cummings, SR; Duong, T; Kenyon, E; Krueger, KA; Whitehead, M	1
Kruse, HP	1
Cortet, B	1
Sherman, S	1
Barrett-Connor, E	1
Bjarnason, NH; Christiansen, C; Delmas, PD; Duong, T; Mitlak, B; Sarkar, S	1
Harper, K; Lips, P; Lu, Y; Oleksik, A; Ott, SM	1
Bauer, DC; Blackwell, T; Chapurlat, RD; Cummings, SR	1
Anderson, PW; Barrett-Connor, E; Cox, DA; Grady, D; Harper, KD; Hoszowski, K; Rautaharju, P; Sashegyi, A	1
Johnell, O; Lu, Y; Need, AG; Reginster, JY; Scheele, WH; Seeman, E	1
Kearney, CE; Purdie, DW	1
Emons, G; Westphalen, S	1
De Valk-De Roo, G; Evertz, R; Neele, SJ; Netelenbos, JC; Roos, JC	1
Grady, D	1
Akazawa, K	1
Taga, M	1
Boyack, M; Chasson, S; Lookinland, S	1
Adachi, JD; Harper, KD; Maricic, M; Sarkar, S; Wong, M; Wu, W	1
Jarkova, NB; Martenyi, F; Masanauskaite, D; Pavo, I; Smetnik, VP; Walls, EL	1
Kopeć, M; Kucharz, EJ	1
MacIver, DW	1
Dominguez, JE; Shortle, B; Warren, MP	1

Reviews

173 review(s) available for raloxifene hydrochloride and Bone Loss, Perimenopausal

Article	Year
Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2021, Volume: 53, Issue:11 Topics: Aged; Female; Humans; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2021
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcified tissue international, 2023, Volume: 112, Issue:6 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2023
Raloxifene as a treatment option for viral infections. Journal of microbiology (Seoul, Korea), 2021, Volume: 59, Issue:2 Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Repositioning; Estrogen Antagonists; Estrogens; Humans; Molecular Docking Simulation; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; SARS-CoV-2; Selective Estrogen Receptor Modulators	2021
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. The Cochrane database of systematic reviews, 2021, Jul-07, Volume: 7 Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting	2021
Clinical Update on Osteoporosis. Journal of midwifery & women's health, 2019, Volume: 64, Issue:3 Topics: Absorptiometry, Photon; Aged; Bone Density Conservation Agents; Calcitonin; Denosumab; Diagnostic Screening Programs; Diphosphonates; Drug Therapy; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Health Status Indicators; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Teriparatide; Vitamins	2019
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric : the journal of the International Menopause Society, 2019, Volume: 22, Issue:2 Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina	2019
The use of raloxifene in osteoporosis treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2013
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents? Clinical obstetrics and gynecology, 2013, Volume: 56, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Calcitriol; Calcium, Dietary; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2013
Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options. Clinical obstetrics and gynecology, 2013, Volume: 56, Issue:4 Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Calcium, Dietary; Dietary Supplements; Diphosphonates; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Factors; Risk Reduction Behavior; Vitamin D	2013
Postmenopausal osteoporosis. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:6 Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid	2013
Use of SERMs for treatment in postmenopausal women. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 142 Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene	2014
Treatment of post-menopausal osteoporosis: beyond bisphosphonates. Journal of endocrinological investigation, 2015, Volume: 38, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Anabolic Agents; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Remodeling; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Genetic Markers; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2015
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Clinical interventions in aging, 2014, Volume: 9 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Fractures, Bone; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2014
Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas, 2008, Jun-20, Volume: 60, Issue:2 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs, 2008, Volume: 68, Issue:14 Topics: Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
[Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Clinical calcium, 2008, Volume: 18, Issue:10 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2008
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clinical interventions in aging, 2008, Volume: 3, Issue:4 Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators	2008
[Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover]. Clinical calcium, 2009, Volume: 19, Issue:8 Topics: Androgens; Biomarkers; Bone and Bones; Bone Remodeling; Bone Resorption; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2009
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Journal of women's health (2002), 2009, Volume: 18, Issue:10 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health	2009
[Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2010
[Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Adiponectin; beta Catenin; Diabetes Mellitus, Type 2; Female; Fractures, Spontaneous; Humans; Hyperlipidemias; Hypertension; Life Style; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Spinal Fractures; Wnt Proteins	2010
[Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Arteriosclerosis; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Venous Thrombosis	2010
[Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Femur; Humans; Osteogenesis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide	2010
[Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Homocysteine; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Estrogen Receptor Modulators; Spinal Fractures	2010
[Effects of SERMs on bone health. Combination therapy with raloxifene]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2010
[Musculoskeletal rehabilitation and bone. Influence of medicines and hormones on musculoskeletal rehabilitation]. Clinical calcium, 2010, Volume: 20, Issue:4 Topics: Accidental Falls; Aging; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Gonadal Steroid Hormones; Humans; Musculoskeletal Diseases; Musculoskeletal System; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Sarcopenia; Vitamin D	2010
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome	2011
A comparison between bisphosphonates and other treatments for osteoporosis. Current pharmaceutical design, 2010, Volume: 16, Issue:27 Topics: Bone Density Conservation Agents; Diphosphonates; Drug Costs; Drug Monitoring; Female; France; Humans; Male; Medication Adherence; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes	2010
Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis. Current medical research and opinion, 2010, Volume: 26, Issue:11 Topics: Aged; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Thiophenes; Treatment Outcome	2010
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators	2011
[Selective estrogen receptor modulators: focus on bazedoxifene]. Minerva ginecologica, 2011, Volume: 63, Issue:3 Topics: Female; Humans; Indoles; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2011
Long-term raloxifene for postmenopausal osteoporosis. Current medical research and opinion, 2011, Volume: 27, Issue:9 Topics: Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Time Factors	2011
Real-world challenges of treating osteoporosis. The American journal of managed care, 2011, Volume: 17 Suppl 6 Topics: Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Disease Management; Female; Hormone Replacement Therapy; Humans; Life Style; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment	2011
Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2012, Volume: 21, Issue:12 Topics: Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Switzerland	2012
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
Raloxifene: recent information on skeletal and non-skeletal effects. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterus	2002
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrine reviews, 2002, Volume: 23, Issue:4 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2002
[Selective estrogen receptor modulators (SERMs) in the practice]. Magyar onkologia, 2002, Volume: 46, Issue:2 Topics: Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2002
Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS drug reviews, 2002,Fall, Volume: 8, Issue:3 Topics: Animals; Breast Neoplasms; Cardiovascular System; Central Nervous System; Cognition; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Hypothalamo-Hypophyseal System; Male; Neuroprotective Agents; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Neurotransmitter; Structure-Activity Relationship; Tamoxifen; Thiophenes; Uterus	2002
[Specific estrogen receptor modulators (SERMs)]. Presse medicale (Paris, France : 1983), 2002, Sep-07, Volume: 31, Issue:28 Topics: Adult; Antineoplastic Agents, Hormonal; Bone and Bones; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Endometrium; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Lipid Metabolism; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Polyunsaturated Alkamides; Postmenopause; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors	2002
Bioidentical hormone replacement therapy. Customizing care for perimenopausal and menopausal women. Advance for nurse practitioners, 2002, Volume: 10, Issue:11 Topics: Chemistry, Pharmaceutical; Climacteric; Drug Combinations; Drug Compounding; Drug Monitoring; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Medroxyprogesterone Acetate; Menopause; Osteoporosis, Postmenopausal; Patient Care Planning; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2002
[Osteoporosis: prevention of bone loss and fractures]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed	2002
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. The New England journal of medicine, 2003, Feb-13, Volume: 348, Issue:7 Topics: Bone and Bones; Breast; Breast Neoplasms; Central Nervous System; Coronary Disease; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Urogenital System	2003
[Osteoporosis]. Der Internist, 2002, Volume: 43, Issue:12 Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid	2002
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. Journal of medicinal chemistry, 2003, Mar-27, Volume: 46, Issue:7 Topics: Animals; Antineoplastic Agents; Drug Resistance; Endometrial Neoplasms; Estradiol Congeners; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Humans; Models, Molecular; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Steroids; Structure-Activity Relationship; Tamoxifen	2003
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinology and metabolism clinics of North America, 2003, Volume: 32, Issue:1 Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2003
Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert opinion on drug safety, 2002, Volume: 1, Issue:1 Topics: Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Vitamin D	2002
Osteoporosis: evaluation and treatment. Current women's health reports, 2003, Volume: 3, Issue:5 Topics: Aged; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Education as Topic; Raloxifene Hydrochloride; Vitamin D; Women's Health	2003
Medical treatment of vertebral osteoporosis. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2003, Volume: 12 Suppl 2 Topics: Aged; Calcitonin; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2003
[Treatment of osteoporosis]. Orvosi hetilap, 2003, Aug-03, Volume: 144, Issue:31 Topics: Bone Density; Calcitonin; Calcium Compounds; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Male; Norpregnenes; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2003
The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Annals of the New York Academy of Sciences, 2003, Volume: 997 Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Treatment Outcome; United States; Women's Health	2003
[Treatment of postmenopausal osteoporosis]. Anales del sistema sanitario de Navarra, 2003, Volume: 26 Suppl 3 Topics: Calcitonin; Diet; Dietary Supplements; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
[Raloxifene and breast: from the SERMs concept to its place in clinical practice]. Gynecologie, obstetrique & fertilite, 2004, Volume: 32, Issue:1 Topics: Aged; Animals; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2004
An approach to postmenopausal osteoporosis treatment: a case study review. Journal of the American Academy of Nurse Practitioners, 2003, Volume: 15, Issue:12 Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D	2003
Osteoporosis management in the new millennium. Primary care, 2003, Volume: 30, Issue:4 Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2003
[MORE study(raloxifene)]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Biomarkers; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Venous Thrombosis	2004
[Raloxifene hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Arteriosclerosis; Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocrine regulations, 2003, Volume: 37, Issue:4 Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
[Postmenopausal osteoporosis]. Orvosi hetilap, 2004, Jan-04, Volume: 145, Issue:1 Topics: Absorptiometry, Photon; Anabolic Agents; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Isoflavones; Motor Activity; Norpregnenes; Osteoporosis, Postmenopausal; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D; Weight-Bearing	2004
A reappraisal of therapeutic approaches to osteoporosis. Aging clinical and experimental research, 2004, Volume: 16 Suppl, Issue:3 Topics: Alkaline Phosphatase; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2004
Pharmacologic prevention of osteoporotic fractures. American family physician, 2004, Oct-01, Volume: 70, Issue:7 Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators	2004
Drugs for prevention and treatment of postmenopausal osteoporosis. Treatment guidelines from the Medical Letter, 2002, Volume: 1, Issue:3 Topics: Aged; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2002
Treating osteoporosis in post-menopausal women: a case approach. Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:10 Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2004
[Compression vertebral fracture in osteoporosis--prevention and treatment]. Reumatizam, 2004, Volume: 51, Issue:2 Topics: Aged; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures	2004
[Contribution of bone quality to fracture risk]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone and Bones; Bone Density; Bone Matrix; Bone Remodeling; Calcification, Physiologic; Controlled Clinical Trials as Topic; Female; Femoral Neck Fractures; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone Density; Elbow; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2004
[Effects of raloxifene on other organs without bone: uterus]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Myometrium; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Diseases	2004
[Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Biomarkers; Bone and Bones; Bone Density; Controlled Clinical Trials as Topic; Female; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Predictive Value of Tests; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2004
[Additional effect of SERM: mammary gland]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2004
[Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Female; Femoral Neck Fractures; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Additional effect of SERM: central nervous system]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Attention; Cells, Cultured; Choline O-Acetyltransferase; Cognition; Female; Hippocampus; Humans; Memory; Neurites; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Serotonin; Selective Estrogen Receptor Modulators; Stimulation, Chemical	2004
[Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Venous Thrombosis	2004
[SERM and quality of bone]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone and Bones; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Which is the better choice, estrogen or SERMs in postmenopausal women?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Hip Fractures; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterine Hemorrhage	2004
[Who are the candidates for the treatment by raloxifen ?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exercise Therapy; Female; Fractures, Bone; Humans; Motor Activity; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:1 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors	2005
[Treatment of osteoporosis with antiresorptive drugs]. Ugeskrift for laeger, 2005, Feb-21, Volume: 167, Issue:8 Topics: Bone Density; Bone Resorption; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Estradiol; Estrogens, Conjugated (USP); Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2005
[Effects of estrogen and selective estrogen receptor modulators on osteoporosis]. Clinical calcium, 2005, Volume: 15, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrogens; Evidence-Based Medicine; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2005
Pharmacological management of severe postmenopausal osteoporosis. Drugs & aging, 2005, Volume: 22, Issue:5 Topics: Aged; Calcitonin; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Teriparatide	2005
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health technology assessment (Winchester, England), 2005, Volume: 9, Issue:22 Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide	2005
Raloxifene for prevention of osteoporotic fractures. American family physician, 2005, Jul-01, Volume: 72, Issue:1 Topics: Evidence-Based Medicine; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Patient Selection; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
Oral antiresorptive therapy. Current osteoporosis reports, 2004, Volume: 2, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome	2004
Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug safety, 2005, Volume: 28, Issue:8 Topics: Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2005
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2 Topics: Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures	2006
A rational approach to evidence gaps in the management of osteoporosis. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors	2005
Review of treatment modalities for postmenopausal osteoporosis. Southern medical journal, 2005, Volume: 98, Issue:10 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency	2005
Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Best practice & research. Clinical rheumatology, 2005, Volume: 19, Issue:6 Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options. Treatments in endocrinology, 2006, Volume: 5, Issue:1 Topics: Alendronate; Bone Density; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide	2006
Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clinical orthopaedics and related research, 2006, Volume: 443 Topics: Animals; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2006
[Raloxifene in postmenopausal women]. Gynecologie, obstetrique & fertilite, 2006, Volume: 34, Issue:2 Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators	2006
Raloxifene: bone and cardiovascular effects. Journal of endocrinological investigation, 2005, Volume: 28, Issue:10 Suppl Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cardiovascular System; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2005
[Molecular mechanism tissue-specific actions of selective estrogen receptor modulators]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2006, Volume: 43, Issue:2 Topics: Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2006
[Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient]. Reumatizam, 2005, Volume: 52, Issue:2 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
[SERMs for treatment of osteoporosis: state-of-the-art and perspectives]. Gynecologie, obstetrique & fertilite, 2006, Volume: 34, Issue:5 Topics: Breast Neoplasms; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Long-term experience with alendronate in the treatment of osteoporosis. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9 Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid	2006
[Postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Jun-28, Volume: Suppl 2 Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride	2006
Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:12 Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Male; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes	2006
The science of selective estrogen receptor modulators: concept to clinical practice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-01, Volume: 12, Issue:17 Topics: Breast Neoplasms; Female; Humans; Models, Biological; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2006
[Selective estrogen receptor modulators (SERMs)]. Clinical calcium, 2006, Volume: 16, Issue:9 Topics: Breast Neoplasms; Female; Humans; Organ Specificity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke	2006
[SERM]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:9 Topics: Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
[Drug treatment of postmenopausal osteoporosis. What's New in 2006]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors	2006
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs, 2006, Volume: 66, Issue:16 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes	2006
SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute, 2007, Mar-07, Volume: 99, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Evidence-Based Medicine; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2007
[Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis]. Clinical calcium, 2007, Volume: 17, Issue:9 Topics: Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2007
[Where do SERMs stand in the light of clinical application?]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Binding, Competitive; Breast Neoplasms; Drug Design; Female; Humans; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2007
[CORE study]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Time Factors	2007
[Effects of SERM on the cardiovascular system]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke	2007
[Evidence of raloxifene on postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2007
Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thrombosis and haemostasis, 2008, Volume: 99, Issue:2 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Patient Selection; Postmenopause; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2008
[Assessment of bone quality. Bone quality and osteoporosis treatment]. Clinical calcium, 2008, Volume: 18, Issue:3 Topics: Aging; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcification, Physiologic; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
[Osteoporosis in the elderly--diagnosis and treatment]. MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7 Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D	2005
Raloxifene for older women: a review of the literature. Clinical interventions in aging, 2008, Volume: 3, Issue:1 Topics: Bone and Bones; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2008
Clinical potential of new antiestrogens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2 Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene	1997
Selective estrogen receptor modulators and postmenopausal women's health. Journal of women's health, 1997, Volume: 6, Issue:5 Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Women's Health	1997
Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1998, Volume: 217, Issue:1 Topics: Bone Resorption; Cholesterol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Uterus	1998
Status of antiestrogen breast cancer prevention trials. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:3 Suppl 5 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States	1998
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms	1998
Management of postmenopausal osteoporosis for primary care. Menopause (New York, N.Y.), 1998,Summer, Volume: 5, Issue:2 Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Referral and Consultation; Risk Factors; Sodium Fluoride	1998
Ultrasound and alendronate: new tools for osteoporosis screening and treatment. Cleveland Clinic journal of medicine, 1998, Volume: 65, Issue:8 Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Prognosis; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Vitamin D	1998
Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. Journal of women's health, 1998, Volume: 7, Issue:7 Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	1998
Clinical effects of raloxifene hydrochloride in women. Annals of internal medicine, 1999, Mar-02, Volume: 130, Issue:5 Topics: Animals; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen	1999
Using osteoporosis management to reduce fractures in elderly women. The Nurse practitioner, 1999, Volume: 24, Issue:3 Topics: Accidental Falls; Aged; Calcitonin; Calcium; Estrogen Antagonists; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Geriatric Assessment; Humans; Nutritional Physiological Phenomena; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Raloxifene Hydrochloride; Risk Factors	1999
[Estrogen receptor and selective estrogen receptor modulators (SERMs)]. Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:5 Topics: Arteriosclerosis; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen	1999
Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women. Mayo Clinic proceedings, 1999, Volume: 74, Issue:6 Topics: Aged; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmenopausal; Phytoestrogens; Piperidines; Plant Preparations; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	1999
Prevention of osteoporosis and fractures. American family physician, 1999, Volume: 60, Issue:1 Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D	1999
Clinical efficacy of raloxifene in postmenopausal women. European journal of obstetrics, gynecology, and reproductive biology, 1999, Volume: 85, Issue:1 Topics: Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	1999
Postmenopausal osteoporosis. Obstetrical & gynecological survey, 1999, Volume: 54, Issue:8 Topics: Biomarkers; Bone Density; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Life Style; Mass Screening; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk Factors	1999
Treatment considerations in the management of age-related osteoporosis. The American journal of the medical sciences, 1999, Volume: 318, Issue:3 Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Severity of Illness Index	1999
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women]. Nederlands tijdschrift voor geneeskunde, 1999, Aug-28, Volume: 143, Issue:35 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Raloxifene: a selective estrogen receptor modulator. American family physician, 1999, Sep-15, Volume: 60, Issue:4 Topics: Bone and Bones; Clinical Trials as Topic; Drug Costs; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipids; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Teaching Materials; Uterus	1999
[Results of international clinical trials with raloxifene]. Annales d'endocrinologie, 1999, Volume: 60, Issue:3 Topics: Animals; Clinical Trials as Topic; Female; Humans; International Cooperation; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	1999
Tolerability profile of SERMs. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Animals; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	1999
Choosing the patient for treatment. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Aged; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors	1999
The role of SERMs in the management of postmenopausal osteoporosis. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	1999
Raloxifene to prevent postmenopausal osteoporosis. Drug and therapeutics bulletin, 1999, Volume: 37, Issue:5 Topics: Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	1999
The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:12 Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Genital Neoplasms, Female; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	1999
Selective estrogen receptor modulators and postmenopausal health. Advances in internal medicine, 2000, Volume: 45 Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health	2000
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy]. Schweizerische medizinische Wochenschrift, 1999, Dec-11, Volume: 129, Issue:49 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
[Raloxifene: a selective modulator of estrogen receptors]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1999, Volume: 28, Issue:8 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	1999
[Clinical experience with raloxifene]. Orvosi hetilap, 2000, Jan-30, Volume: 141, Issue:5 Topics: Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
[Alternatives to hormone replacement therapy: raloxifene and tibolone]. Zeitschrift fur arztliche Fortbildung und Qualitatssicherung, 2000, Volume: 94, Issue:3 Topics: Antihypertensive Agents; Bone Density; Climacteric; Estrogen Replacement Therapy; Female; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2000
Postmenopausal osteoporosis management. Current opinion in obstetrics & gynecology, 2000, Volume: 12, Issue:3 Topics: Bone Density; Female; Hormone Replacement Therapy; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Radiography; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Ultrasonography; Women's Health	2000
Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic proceedings, 2000, Volume: 75, Issue:8 Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Chemoprevention of breast cancer. Cancer treatment and research, 2000, Volume: 103 Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs, 2000, Volume: 60, Issue:2 Topics: Bone Remodeling; Breast; Endometrium; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Raloxifene hydrochloride. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Sep-15, Volume: 57, Issue:18 Topics: Administration, Oral; Aged; Biological Availability; Bone and Bones; Female; Half-Life; Humans; Intestinal Absorption; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tissue Distribution	2000
Building bone. Advance for nurse practitioners, 2000, Volume: 8, Issue:1 Topics: Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Middle Aged; Nurse Practitioners; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2000
Prevention of osteoporotic fractures in post-menopausal women. Bailliere's best practice & research. Clinical endocrinology & metabolism, 2000, Volume: 14, Issue:2 Topics: Calcitonin; Calcium; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2000
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures]. Nederlands tijdschrift voor geneeskunde, 2000, Oct-07, Volume: 144, Issue:41 Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine	2000
[Indications for hormone replacement therapy]. Therapeutische Umschau. Revue therapeutique, 2000, Volume: 57, Issue:10 Topics: Aged; Alzheimer Disease; Anabolic Agents; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Thrombosis	2000
[Therapeutic strategies for osteoporosis]. Annales de medecine interne, 2000, Volume: 151, Issue:6 Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Nutritional Physiological Phenomena; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D	2000
Focus on primary care postmenopausal osteoporosis: an update. Obstetrical & gynecological survey, 2000, Volume: 55, Issue:12 Suppl 3 Topics: Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2000, Volume: 11 Suppl 6 Topics: Biomarkers; Bone Density; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogens; Female; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Periodicity; Prognosis; Raloxifene Hydrochloride; Risk Assessment; Terminology as Topic	2000
Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2000, Volume: 11 Suppl 6 Topics: Biomarkers; Bone Density; Bone Remodeling; Diphosphonates; Estradiol; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Treatment Outcome	2000
Novel agents to modulate oestrogen action. British medical bulletin, 2000, Volume: 56, Issue:3 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Therapy for osteoporosis. Journal of the South Carolina Medical Association (1975), 2001, Volume: 97, Issue:3 Topics: Aged; Aged, 80 and over; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:1 Topics: Aged; Animals; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2001
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Archives of dermatology, 2001, Volume: 137, Issue:4 Topics: Adult; Age Factors; Aged; Calcitonin; Calcium; Controlled Clinical Trials as Topic; Densitometry; Diphosphonates; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Skin Diseases; Time Factors; Vitamin D	2001
Cardiovascular effects of raloxifene hydrochloride. Cardiovascular drug reviews, 2001,Spring, Volume: 19, Issue:1 Topics: Animals; Bone and Bones; Brain; Breast Neoplasms; Cardiovascular System; Endothelium, Vascular; Female; Genitalia, Female; Humans; Lipids; Osteoporosis, Postmenopausal; Pituitary Gland; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2001
Tamoxifen, screening and new oestrogen receptor modulators. Best practice & research. Clinical obstetrics & gynaecology, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endosonography; Female; Humans; Hysteroscopy; Mass Screening; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Tamoxifen	2001
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms	2001
Preventing and treating osteoporosis: strategies at the millennium. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Raloxifene: risks and benefits. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Hot Flashes; Humans; Morbidity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Thromboembolism	2001
Selective estrogen receptor modulators. Climacteric : the journal of the International Menopause Society, 1998, Volume: 1, Issue:2 Topics: Aged; Animals; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	1998
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Climacteric : the journal of the International Menopause Society, 1998, Volume: 1, Issue:2 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Heart Diseases; Humans; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Survivors	1998
[Advance in the treatment of postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Aged; Amino Acids; Biomarkers; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
[Drugs in development for the treatment of osteoporosis:Raloxifene]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Bone Density; Bone Remodeling; Estrogen Antagonists; Female; Fractures, Stress; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
Efficacy of raloxifene for treatment of menopause: a systematic review. Journal of the American Academy of Nurse Practitioners, 2002, Volume: 14, Issue:4 Topics: Aged; Bone Density; Endometrium; Female; Heart; Humans; Lipids; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Treatment Outcome	2002
[The effect of raloxifene on bone tissue in postmenopausal women]. Polskie Archiwum Medycyny Wewnetrznej, 2001, Volume: 106, Issue:6 Topics: Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen	2001
Review of raloxifene and its clinical applications in osteoporosis. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6 Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Diseases	2002
Use of alternative therapies in menopause. Best practice & research. Clinical obstetrics & gynaecology, 2002, Volume: 16, Issue:3 Topics: Cardiovascular Diseases; Estrogens; Female; Humans; Hypercholesterolemia; Isoflavones; Lignans; Menopause; Middle Aged; Neoplasms; Osteoporosis, Postmenopausal; Phytotherapy; Plant Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002

Trials

163 trial(s) available for raloxifene hydrochloride and Bone Loss, Perimenopausal

Article	Year
Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial. Current rheumatology reviews, 2023, Volume: 19, Issue:1 Topics: Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2023
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene. Calcified tissue international, 2023, Volume: 112, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2023
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Current medical research and opinion, 2020, Volume: 36, Issue:11 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome	2020
A pilot study comparing daily teriparatide with monthly cycles of teriparatide and raloxifene. Archives of osteoporosis, 2021, 04-15, Volume: 16, Issue:1 Topics: Aged; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Pilot Projects; Raloxifene Hydrochloride; Teriparatide	2021
Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial. Circulation. Cardiovascular quality and outcomes, 2013, Mar-01, Volume: 6, Issue:2 Topics: Age Factors; Aged; Bone Density Conservation Agents; Chi-Square Distribution; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Heart Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Prognosis; Proportional Hazards Models; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Sex Factors; Time Factors	2013
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:10 Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome	2013
Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens. Menopause (New York, N.Y.), 2013, Volume: 20, Issue:11 Topics: Bone Density; Dose-Response Relationship, Drug; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Treatment Outcome	2013
Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:11 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Drug Administration Schedule; Drug Monitoring; Drug Packaging; Electrical Equipment and Supplies; England; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Tablets	2013
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. Journal of endocrinological investigation, 2013, Volume: 36, Issue:11 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Humans; Hyperparathyroidism, Primary; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2013
Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study. Health and quality of life outcomes, 2013, Nov-05, Volume: 11 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Australia; Bone Density Conservation Agents; Cervical Vertebrae; European Union; Female; Forecasting; Fractures, Bone; Health Status; Humans; Middle Aged; New Zealand; North America; Osteoporosis, Postmenopausal; Patient Satisfaction; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires	2013
Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway. Drug metabolism and drug interactions, 2014, Volume: 29, Issue:2 Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Osteoprotegerin; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Selective Estrogen Receptor Modulators; Wnt Signaling Pathway	2014
Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:8 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide; Time Factors; Treatment Outcome	2014
Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iranian journal of kidney diseases, 2014, Volume: 8, Issue:6 Topics: Administration, Oral; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic	2014
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:8 Topics: Adult; Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Procollagen; Raloxifene Hydrochloride	2016
Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:7 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Humans; Indoles; Mexico; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Treatment Outcome	2016
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine	2008
Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. Journal of endocrinological investigation, 2008, Volume: 31, Issue:5 Topics: Aged; Bone Density Conservation Agents; Calcium; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Vitamin D	2008
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone, 2009, Volume: 44, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid	2009
Cross-geographic region differences in quality of life in women with and without vertebral fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:10 Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. The Journal of bone and joint surgery. American volume, 2009, Volume: 91, Issue:6 Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Severity of Illness Index; Spinal Fractures; Teriparatide; Treatment Outcome	2009
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Drug Administration Schedule; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome; United States; Vitamin D	2009
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertility and sterility, 2009, Volume: 92, Issue:3 Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Collagen Type I; Dose-Response Relationship, Drug; Double-Blind Method; Estrogens; Estrogens, Conjugated (USP); Female; Hip Joint; Humans; Indoles; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2009
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:2 Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Japan; Medication Adherence; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Patient Dropouts; Raloxifene Hydrochloride; Statistics as Topic; Surveys and Questionnaires; Time Factors	2010
Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:7 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dose-Response Relationship, Drug; Double-Blind Method; Endometrium; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Vasomotor System	2010
Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial. European journal of endocrinology, 2010, Volume: 162, Issue:2 Topics: Aged; Aged, 80 and over; Body Composition; Bone Density Conservation Agents; Double-Blind Method; Female; Hand Strength; Humans; Isometric Contraction; Muscle Strength; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Residence Characteristics	2010
Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels. Clinical nephrology, 2009, Volume: 72, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunoradiometric Assay; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Renal Dialysis; Retrospective Studies; Treatment Outcome	2009
Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:4 Topics: Aged; Arthralgia; Back Pain; Bone Density Conservation Agents; Female; Humans; Knee Joint; Middle Aged; Osteoarthritis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2010
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus	2010
Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Current medical research and opinion, 2010, Volume: 26, Issue:8 Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; Treatment Outcome; Vitamin D	2010
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC musculoskeletal disorders, 2010, Jun-22, Volume: 11 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2010
Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Premenopause; Procollagen; Raloxifene Hydrochloride; Reference Values; Treatment Outcome	2011
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney international, 2011, Volume: 79, Issue:2 Topics: Aged; Creatinine; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators	2011
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Annals of the rheumatic diseases, 2011, Volume: 70, Issue:5 Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Female; Glucocorticoids; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prednisone; Raloxifene Hydrochloride; Rheumatic Diseases	2011
Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:3 Topics: Aged; Alendronate; Biomarkers; Bone Density; Cholesterol, HDL; Collagen Type I; Drug Administration Schedule; Drug Monitoring; Female; Femur Neck; Humans; Lipid Metabolism; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Treatment Outcome	2011
Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:5 Topics: Bone and Bones; Bone Density Conservation Agents; Female; Hot Flashes; Humans; Indoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2011
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:3 Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Female; Femur Neck; Hip Joint; Hot Flashes; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Thiophenes; Treatment Outcome	2012
Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:4 Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Calcium; Cell Differentiation; Drug Therapy, Combination; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Osteoblasts; Osteocalcin; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Secondary Prevention; Teriparatide; Vitamin D	2012
Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial. Journal of the American Medical Directors Association, 2012, Volume: 13, Issue:2 Topics: Absorptiometry, Photon; Academic Medical Centers; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Bone Density; Bone Density Conservation Agents; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Middle Aged; Netherlands; Norpregnenes; Osteoporosis, Postmenopausal; Patient Safety; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome	2012
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Endometrial Neoplasms; Endometrium; Female; Genital Diseases, Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Polyps; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Uterine Hemorrhage; Vaginitis; Vulvitis	2012
Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:3 Topics: Bone Density Conservation Agents; Bone Remodeling; Cell Proliferation; Cells, Cultured; Female; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-1beta; Interleukin-4; Interleukin-6; Leukocytes, Mononuclear; Lymphocyte Subsets; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; Receptor Activator of Nuclear Factor-kappa B; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2012
Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:3 Topics: Aged; Aged, 80 and over; Asian People; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Demography; Dietary Supplements; Drug Therapy, Combination; Female; Hip; Humans; Hydroxycholecalciferols; Japan; Lumbar Vertebrae; Middle Aged; Organ Sparing Treatments; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Postmenopause; Raloxifene Hydrochloride	2012
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Finite Element Analysis; Hip; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spine; Teriparatide; Tomography, X-Ray Computed	2013
Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis. Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:3 Topics: Aged; Aged, 80 and over; Biological Factors; Circadian Rhythm; Drug Administration Schedule; Female; Fibrinolysis; Humans; Osteoporosis, Postmenopausal; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Venous Thrombosis	2013
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:8 Topics: Aged; Bone and Bones; Bone Density; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome	2002
Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:9 Topics: Blood Glucose; Bone Diseases, Metabolic; C-Peptide; Estradiol; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Insulin; Italy; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; White People	2002
Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. European journal of endocrinology, 2002, Volume: 147, Issue:4 Topics: Adult; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Luteinizing Hormone; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prolactin; Raloxifene Hydrochloride	2002
Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2002, Volume: 13, Issue:11 Topics: Aged; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures	2002
Jumping exercises with and without raloxifene treatment in healthy elderly women. Journal of bone and mineral metabolism, 2002, Volume: 20, Issue:6 Topics: Absorptiometry, Photon; Aged; Body Mass Index; Bone Density; Calcium; Exercise; Female; Humans; Osteoporosis, Postmenopausal; Patient Compliance; Physical Fitness; Postural Balance; Raloxifene Hydrochloride; Risk Factors; Time Factors; Vitamin D	2002
Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstetrics and gynecology, 2003, Volume: 101, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal; Probability; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Selective Estrogen Receptor Modulators; Sexuality; Treatment Outcome	2003
Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women. American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:2 Topics: Blood Circulation; Double-Blind Method; Endothelium, Vascular; Female; Humans; Lipoproteins, LDL; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vasodilation	2003
A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG : an international journal of obstetrics and gynaecology, 2003, Volume: 110, Issue:2 Topics: Aged; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Humans; Middle Aged; Norethindrone; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Single-Blind Method; Time Factors; Treatment Outcome; Uterine Diseases; Uterine Hemorrhage	2003
Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:5 Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Heart Rate; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:9 Topics: Adult; Aged; Analysis of Variance; Anthropometry; Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Drug Therapy, Combination; Female; Fluorides; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical therapeutics, 2003, Volume: 25, Issue:3 Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Statistics as Topic; Time Factors; Treatment Outcome	2003
Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:10 Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Double-Blind Method; Endometrium; Female; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone, 2003, Volume: 33, Issue:3 Topics: Aged; Bone Density; Bone Diseases, Metabolic; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Risk Reduction Behavior; Spinal Fractures; Treatment Outcome	2003
Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. International journal of tissue reactions, 2003, Volume: 25, Issue:2 Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Cholecalciferol; Clodronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone, 2003, Volume: 33, Issue:4 Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk Factors; Spinal Fractures	2003
Compliance of osteoporotic patients with different treatment regimens. The Israel Medical Association journal : IMAJ, 2003, Volume: 5, Issue:12 Topics: Aged; Alendronate; Attitude to Health; Comorbidity; Female; Humans; Israel; Logistic Models; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone, 2004, Volume: 34, Issue:2 Topics: Aged; Alkaline Phosphatase; Biomarkers; Collagen Type I; Estrogen Antagonists; Female; Humans; Logistic Models; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2004
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density; Drug Monitoring; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Self Administration; Survival Analysis	2004
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clinical therapeutics, 2004, Volume: 26, Issue:2 Topics: Aged; Alendronate; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spain	2004
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. Journal of internal medicine, 2004, Volume: 255, Issue:4 Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Double-Blind Method; Female; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Time Factors; Treatment Outcome	2004
[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis]. Zhonghua yi xue za zhi, 2004, Feb-17, Volume: 84, Issue:4 Topics: 1-Carboxyglutamic Acid; Absorptiometry, Photon; Aged; Bone Density; Collagen; Collagen Type I; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Peptides; Raloxifene Hydrochloride; Treatment Outcome	2004
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:5 Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Drug Interactions; Female; Hip; Humans; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Radiography; Raloxifene Hydrochloride; Teriparatide	2004
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:5 Topics: Analysis of Variance; Bone Density; Evaluation Studies as Topic; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Prospective Studies; Radiography; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Triglycerides	2004
[The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis]. Reumatizam, 2003, Volume: 50, Issue:2 Topics: Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study. Maturitas, 2004, May-28, Volume: 48, Issue:1 Topics: Affect; Case-Control Studies; Cognition; Female; Humans; Libido; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Surveys and Questionnaires	2004
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome	2004
Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial. Chinese medical journal, 2004, Volume: 117, Issue:7 Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2004
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2004, Volume: 18, Issue:4 Topics: Bone Density; Drug Administration Schedule; Drug Therapy, Combination; Endometrium; Female; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prolactin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sulpiride; Treatment Outcome	2004
Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:1 Topics: Aged; Double-Blind Method; Female; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstetrics and gynecology, 2004, Volume: 104, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Incidence; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; United States; Venous Thrombosis	2004
Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. The Journal of family practice, 2004, Volume: 53, Issue:10 Topics: Adult; Aged; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cerebrovascular Disorders; Estrogen Replacement Therapy; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone, 2004, Volume: 35, Issue:5 Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Double-Blind Method; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spine; Tomography, X-Ray Computed; Treatment Outcome	2004
Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:8 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2005
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute, 2004, Dec-01, Volume: 96, Issue:23 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; United States	2004
[SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone Density; Elbow; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2004
Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:12 Topics: Bone Density; Female; Humans; Interleukin-6; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha	2004
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome; United Kingdom	2005
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:1 Topics: Administration, Oral; Aged; Bone Density; Female; Femur Neck; Humans; Liver; Liver Cirrhosis, Biliary; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:8 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Combinations; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Genotype; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. The American journal of psychiatry, 2005, Volume: 162, Issue:4 Topics: Aged; Alzheimer Disease; Cognition Disorders; Comorbidity; Dementia; Female; Geriatric Assessment; Humans; Osteoporosis, Postmenopausal; Placebos; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2005
Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2005, Volume: 14, Issue:10 Topics: Back Pain; Calcium; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Motor Activity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2005
Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Current medical research and opinion, 2005, Volume: 21, Issue:1 Topics: Aged; Cardiovascular Diseases; Chi-Square Distribution; Female; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2005
Raloxifene and colorectal cancer. Journal of women's health (2002), 2005, Volume: 14, Issue:4 Topics: Aged; Bone Density; Colorectal Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors; United States	2005
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2005,Fall, Volume: 8, Issue:3 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Treatment Outcome	2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:9 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Female; Femoral Neck Fractures; Femur Neck; Fracture Healing; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Poisson Distribution; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk; Time Factors; Treatment Outcome	2005
A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Maturitas, 2005, Sep-16, Volume: 52, Issue:1 Topics: Administration, Cutaneous; Administration, Oral; Calcium, Dietary; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Female; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Progesterone; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Vaginal Diseases; Vitamin D	2005
The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1. Acta obstetricia et gynecologica Scandinavica, 2005, Volume: 84, Issue:10 Topics: Administration, Oral; Antigens; Calcium, Dietary; Carboxypeptidase B2; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Plasminogen Activator Inhibitor 1; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thromboembolism; Tissue Plasminogen Activator	2005
Safety assessment of raloxifene over eight years in a clinical trial setting. Current medical research and opinion, 2005, Volume: 21, Issue:9 Topics: Aged; Bone Density; Cardiovascular System; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Venous Thrombosis	2005
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:11 Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Collagen; Collagen Type I; Creatine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Kidney Function Tests; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Phosphorus; Procollagen; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome; Uric Acid; Vomiting	2005
[Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis]. Clinical calcium, 2005, Volume: 15 Suppl 1 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Collagen; Collagen Type I; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Renal Dialysis; Risk; Selective Estrogen Receptor Modulators	2005
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride	2006
Procoagulant state after raloxifene therapy in postmenopausal women. Fertility and sterility, 2005, Volume: 84, Issue:6 Topics: Blood Coagulation; Blood Coagulation Factors; Female; Fibrinogen; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Postmenopause; Prospective Studies; Protein C; Protein Precursors; Prothrombin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thrombosis	2005
The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Current medical research and opinion, 2005, Volume: 21, Issue:12 Topics: Aged; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2005
Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:4 Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Female; Hip; Humans; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Treatment Outcome	2006
Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Health Status; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamphlets; Patient Compliance; Patient Education as Topic; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Spain	2006
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. The American journal of cardiology, 2006, Feb-15, Volume: 97, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2006, Volume: 23, Issue:2 Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Women	2006
The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:5 Topics: Alendronate; Autonomic Nervous System; Bone Density Conservation Agents; Female; Heart; Heart Rate; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:7 Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypertriglyceridemia; Lipids; Lipoproteins; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 2007, Jan-20, Volume: 56, Issue:1 Topics: Bone Density; Collagen; Female; Humans; Interleukin-6; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptide Fragments; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2007
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. Journal of bone and mineral metabolism, 2006, Volume: 24, Issue:4 Topics: Biomarkers; Bone Remodeling; Collagen; Double-Blind Method; Female; Finland; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	2006
Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2006, Volume: 22, Issue:7 Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Renin; Selective Estrogen Receptor Modulators	2006
Assessment of protein oxidation in women using raloxifene. Molecular and cellular biochemistry, 2006, Volume: 290, Issue:1-2 Topics: Aged; Female; Free Radicals; Humans; Middle Aged; Osteoporosis, Postmenopausal; Oxidation-Reduction; Protein Carbonylation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis. Platelets, 2006, Volume: 17, Issue:6 Topics: Aged; Blood Platelets; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Platelet Function Tests; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Statistics, Nonparametric	2006
Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast cancer research and treatment, 2007, Volume: 102, Issue:2 Topics: Aged; Bone Density; Breast Neoplasms; Estradiol; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Incidence; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome; United States	2007
Apoptosis in raloxifene-treated postmenopausal women. Cell biology international, 2007, Volume: 31, Issue:3 Topics: Aged; Apoptosis; Female; Humans; Lymphocytes; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2007
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone, 2007, Volume: 40, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Safety	2007
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The Journal of rheumatology, 2007, Volume: 34, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cross-Sectional Studies; Depression; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prevalence; Quality of Life; Raloxifene Hydrochloride; Spinal Injuries; Treatment Outcome; Vitamin D	2007
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Archives of medical research, 2007, Volume: 38, Issue:2 Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; Erythrocytes; Etidronic Acid; Female; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nitric Oxide; Osteoporosis, Postmenopausal; Oxidative Stress; Oxidoreductases; Raloxifene Hydrochloride; Risedronic Acid	2007
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. Journal of bone and mineral metabolism, 2007, Volume: 25, Issue:2 Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Surveys and Questionnaires	2007
The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertility and sterility, 2007, Volume: 88, Issue:2 Topics: Bone Density Conservation Agents; Drug Combinations; Estrogen Replacement Therapy; Female; Female Urogenital Diseases; Health Status Indicators; Humans; Hydrogen-Ion Concentration; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Vagina; Vaginal Smears; Vitamin D	2007
Carotid artery intima-media thickness after raloxifene treatment. Journal of women's health (2002), 2007, Volume: 16, Issue:3 Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Carotid Arteries; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Tunica Media; Ultrasonography; Women's Health	2007
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Renal failure, 2007, Volume: 29, Issue:4 Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid	2007
Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. Calcified tissue international, 2007, Volume: 81, Issue:3 Topics: Apoptosis; Bone Density Conservation Agents; Cell Count; Female; Humans; Immunohistochemistry; Osteocytes; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2007
Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. European cytokine network, 2007, Volume: 18, Issue:3 Topics: Amino Acids; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Cytokines; Female; Humans; Interleukin-6; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha; Vitamin D	2007
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:3 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride	2008
Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis. Endocrine journal, 2007, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholesterol, LDL; Collagen Type I; Female; Humans; Japan; Lipid Metabolism; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Triglycerides	2007
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Treatment Outcome	2008
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:1 Topics: Aged; Australia; Bone Density; Bone Density Conservation Agents; Canada; Europe; Female; Femur Neck; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide; United States	2008
Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis. Endocrine journal, 2008, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Follow-Up Studies; Humans; Japan; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride	2008
Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocrine journal, 2008, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Treatment Outcome	2008
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Femur; Follow-Up Studies; Humans; Incidence; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; United States	2008
Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:8 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Norpregnenes; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Drug Combinations; Female; Humans; Hypercalcemia; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Teriparatide	2008
Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis. Journal of bone and mineral metabolism, 2008, Volume: 26, Issue:2 Topics: Aged; Aged, 80 and over; Asian People; Biomarkers; Bone and Bones; Bone Density; Female; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors	2008
Effect of raloxifene on the vaginal epithelium of postmenopausal women. European journal of obstetrics, gynecology, and reproductive biology, 2008, Volume: 139, Issue:2 Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vagina	2008
The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology : JASN, 2008, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Female; Humans; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures	2008
Raloxifene has favourable effects on metabolic parameters but has no effect on left ventricular function in postmenopausal women. Pharmacological research, 2008, Volume: 57, Issue:5 Topics: Aged; Diastole; Echocardiography, Doppler, Pulsed; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Systole; Ventricular Function, Left	2008
A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:6 Topics: Aged; Biomarkers; Biopsy; Double-Blind Method; Endometrium; Estrogen Antagonists; Estrogens; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Raloxifene Hydrochloride; Uterus	1996
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. The New England journal of medicine, 1997, Dec-04, Volume: 337, Issue:23 Topics: Bone Density; Cholesterol; Cholesterol, LDL; Double-Blind Method; Endometrium; Estrogen Antagonists; Female; Hip Joint; Hot Flashes; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride	1997
Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women. Calcified tissue international, 1998, Volume: 63, Issue:4 Topics: Adult; Africa; Alkaline Phosphatase; Analysis of Variance; Australia; Biomarkers; Bone and Bones; Bone Remodeling; Collagen; Collagen Type I; Double-Blind Method; Estrogen Antagonists; Europe; Female; Humans; Hysterectomy; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Piperidines; Raloxifene Hydrochloride	1998
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:11 Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Chi-Square Distribution; Double-Blind Method; Estrogen Antagonists; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Spinal Fractures	1998
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology, 1999, Volume: 24, Issue:1 Topics: Adult; Affect; Aged; Cognition; Depression; Double-Blind Method; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Psychological Tests; Raloxifene Hydrochloride; Safety	1999
Raloxifene: designer estrogen for preventing postmenopausal osteoporosis. Canadian family physician Medecin de famille canadien, 1999, Volume: 45 Topics: Bone Density; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Estrogen Antagonists; Estrogens; Evaluation Studies as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Raloxifene Hydrochloride; Time Factors	1999
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, Jun-16, Volume: 281, Issue:23 Topics: Aged; Breast Neoplasms; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Thromboembolism	1999
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, Aug-18, Volume: 282, Issue:7 Topics: Adult; Aged; Bone Density; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Radiography; Raloxifene Hydrochloride; Risk; Spinal Fractures	1999
[Effects of raloxifene on bone loss and fracture risk in the menopausal woman]. Contraception, fertilite, sexualite (1992), 1999, Volume: 27, Issue:12 Topics: Aged; Bone Density; Female; Humans; Lipids; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1999, Volume: 10, Issue:4 Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Calcium; Cholecalciferol; Cholesterol; Cholesterol, LDL; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	1999
Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA, 2000, Mar-08, Volume: 283, Issue:10 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Time Factors	2000
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:7 Topics: Aged; Bone Density; Emotions; Estrogen Antagonists; Female; Health Status; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2000
Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures? The Western journal of medicine, 2000, Volume: 173, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2000
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Breast; Breast Neoplasms; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Image Interpretation, Computer-Assisted; Mammography; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:1 Topics: Aged; Alkaline Phosphatase; Bone Density; Calcium; Creatinine; Female; Femur Neck; Humans; Hyperparathyroidism; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors	2001
[Treatment of postmenopausal osteoporosis with raloxifene]. Bratislavske lekarske listy, 2000, Volume: 101, Issue:9 Topics: Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:3 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Aging; Alkaline Phosphatase; Bone Density; Calcifediol; Calcium; Cholecalciferol; Female; Humans; Immunoradiometric Assay; Middle Aged; Nutritional Status; Osteoporosis, Postmenopausal; Parathyroid Hormone; Postmenopause; Radioimmunoassay; Raloxifene Hydrochloride; Seasons	2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast cancer research and treatment, 2001, Volume: 65, Issue:2 Topics: Aged; Aged, 80 and over; Australia; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Europe; Female; Follow-Up Studies; Humans; Incidence; Mammography; Middle Aged; New Zealand; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Ultrasonography, Mammary; United States	2001
Cognitive function in postmenopausal women treated with raloxifene. The New England journal of medicine, 2001, Apr-19, Volume: 344, Issue:16 Topics: Aged; Cognition; Cognition Disorders; Female; Hot Flashes; Humans; Memory; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis. Clinical endocrinology, 2001, Volume: 54, Issue:5 Topics: Aged; Calcium; Cross-Sectional Studies; Double-Blind Method; Edetic Acid; Female; Homeostasis; Humans; Infusions, Intravenous; Linear Models; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:6 Topics: Aged; Cross-Sectional Studies; Double-Blind Method; Female; Glucose; Homeostasis; Human Growth Hormone; Humans; Insulin; Insulin-Like Growth Factor I; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Recombinant Proteins; Selective Estrogen Receptor Modulators	2001
Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid : official journal of the American Thyroid Association, 2001, Volume: 11, Issue:8 Topics: Aged; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Reference Values; Selective Estrogen Receptor Modulators; Thyroid Gland; Thyrotropin; Thyroxine; Thyroxine-Binding Proteins; Triiodothyronine	2001
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:1 Topics: Aged; Bone Density; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2002
Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA, 2002, Jan-09, Volume: 287, Issue:2 Topics: Aged; Breast Neoplasms; Estradiol; Female; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Venous Thrombosis	2002
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:11 Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Chi-Square Distribution; Collagen; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Logistic Models; Multivariate Analysis; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2001
Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:2 Topics: Aged; Biopsy; Bone Density; Bone Resorption; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:12 Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Raloxifene Hydrochloride; Regression Analysis; Selective Estrogen Receptor Modulators	2001
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002, Feb-20, Volume: 287, Issue:7 Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Lipoproteins; Myocardial Ischemia; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Stroke; Survival Analysis	2002
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:3 Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Double-Blind Method; Drug Synergism; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone, 2002, Volume: 30, Issue:4 Topics: Bone Density; Estrogens; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Archives of internal medicine, 2002, May-27, Volume: 162, Issue:10 Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2002
Mood effect of raloxifene in postmenopausal women. Maturitas, 2002, May-20, Volume: 42, Issue:1 Topics: Administration, Oral; Depression; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Surveys and Questionnaires	2002

Other Studies

226 other study(ies) available for raloxifene hydrochloride and Bone Loss, Perimenopausal

Article	Year
Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis. Calcified tissue international, 2022, Volume: 111, Issue:1 Topics: Aged; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2022
Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:7 Topics: Bone Density; Bone Density Conservation Agents; Denosumab; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Spinal Fractures	2022
Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women. Scientific reports, 2022, 05-03, Volume: 12, Issue:1 Topics: Aged; Cholecalciferol; Female; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Postmenopause; Prospective Studies; Quality of Life; Raloxifene Hydrochloride	2022
Development and evaluation of raloxifene hydrochloride-loaded subdermal implants using hot-melt extrusion technology. International journal of pharmaceutics, 2022, Jun-25, Volume: 622 Topics: Drug Compounding; Drug Liberation; Female; Hot Melt Extrusion Technology; Hot Temperature; Humans; Osteoporosis, Postmenopausal; Pharmaceutical Preparations; Raloxifene Hydrochloride	2022
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation. Microbiology spectrum, 2022, 06-29, Volume: 10, Issue:3 Topics: Animals; Antimalarials; Female; Heme; Hemeproteins; Hemoglobins; Humans; Indoles; Malaria; Malaria, Falciparum; Male; Mice; Neoplasms; Osteoporosis, Postmenopausal; Plasmodium falciparum; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2022
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022, Volume: 28, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid	2022
Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability. Drug delivery, 2022, Volume: 29, Issue:1 Topics: Animals; Biological Availability; Female; Humans; Nanoparticles; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Serum Albumin, Human	2022
A matrix dispersion based on phospholipid complex system: preparation, lymphatic transport, and pharmacokinetics. Drug development and industrial pharmacy, 2020, Volume: 46, Issue:4 Topics: Administration, Oral; Animals; Biological Availability; Bone Density Conservation Agents; Calorimetry, Differential Scanning; Chylomicrons; Cycloheximide; Drug Liberation; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Models, Animal; Osteoporosis, Postmenopausal; Particle Size; Phospholipids; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Solubility; Tablets; X-Ray Diffraction	2020
Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:1(Special) Topics: Aged; Bone and Bones; Bone Density; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators	2020
Design and development of a commercially viable Nanomedicine (London, England), 2020, Volume: 15, Issue:12 Topics: Administration, Intranasal; Biological Availability; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2020
Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis. Disease markers, 2020, Volume: 2020 Topics: Aged; Aged, 80 and over; Animals; Bone Density Conservation Agents; Disease Models, Animal; Epoxide Hydrolases; Female; Genotyping Techniques; Humans; Membrane Proteins; Mice; Middle Aged; Osteoporosis, Postmenopausal; Pharmacogenomic Variants; Raloxifene Hydrochloride; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Serine Endopeptidases; Treatment Outcome	2020
Therapeutic potential of annatto tocotrienol with self-emulsifying drug delivery system in a rat model of postmenopausal bone loss. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 137 Topics: Absorptiometry, Photon; Animals; Bixaceae; Bone and Bones; Bone Density Conservation Agents; Calcium; Carotenoids; Drug Delivery Systems; Emulsions; Female; Humans; Malondialdehyde; Osteoporosis, Postmenopausal; Ovariectomy; Plant Extracts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tocotrienols; X-Ray Microtomography	2021
Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers. The Journal of pharmacy and pharmacology, 2021, Jun-08, Volume: 73, Issue:7 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cathepsins; Cell Proliferation; Estrogens; Female; Humans; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Pinus; Plant Extracts; Porosity; Raloxifene Hydrochloride; Rats; Receptor Activator of Nuclear Factor-kappa B; Treatment Outcome	2021
Selective Estrogen Receptor Modulators in Gynecology Practice. Clinical obstetrics and gynecology, 2021, 12-01, Volume: 64, Issue:4 Topics: Breast Neoplasms; Estrogens, Conjugated (USP); Female; Gynecology; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2021
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Annals of internal medicine, 2017, 06-06, Volume: 166, Issue:11 Topics: Bone Diseases, Metabolic; Calcium, Dietary; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Vitamin D	2017
Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis. Archives of oral biology, 2018, Volume: 85 Topics: Alveolar Bone Loss; Animals; Bone Density; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Female; Humans; Mice; Osteoblasts; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2018
Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. Archives of osteoporosis, 2018, Mar-22, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drug Utilization; Female; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; Vitamin D	2018
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Archives of osteoporosis, 2018, Mar-21, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; United States; Zoledronic Acid	2018
Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model. The spine journal : official journal of the North American Spine Society, 2018, Volume: 18, Issue:10 Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Diabetes Mellitus, Experimental; Diphosphonates; Disease Models, Animal; Female; Humans; Lumbar Vertebrae; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Peptides; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Streptozocin; X-Ray Microtomography	2018
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 2019, 05-01, Volume: 104, Issue:5 Topics: Absorptiometry, Photon; Accidental Falls; Bone Density Conservation Agents; Calcitonin; Calcium; Clinical Decision-Making; Denosumab; Diphosphonates; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Patient Preference; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Teriparatide; Vitamin D	2019
Raloxifene retards cartilage degradation and improves subchondral bone micro-architecture in ovariectomized rats with patella baja-induced - patellofemoral joint osteoarthritis. Osteoarthritis and cartilage, 2020, Volume: 28, Issue:3 Topics: ADAMTS4 Protein; Aggrecans; Animals; Bone and Bones; Bone Remodeling; Cartilage, Articular; Caspase 3; Cell Count; Collagen Type I; Collagen Type II; Femur; Humans; Immunohistochemistry; Matrix Metalloproteinase 13; Osteoarthritis, Knee; Osteocalcin; Osteoclasts; Osteoporosis, Postmenopausal; Ovariectomy; Patella; Patellar Ligament; Patellofemoral Joint; Peptide Fragments; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; X-Ray Microtomography	2020
Diabetes mellitus in women can be RUTHless: lessons from the Raloxifene Use for The Heart (RUTH) Trial. Circulation. Cardiovascular quality and outcomes, 2013, Mar-01, Volume: 6, Issue:2 Topics: Bone Density Conservation Agents; Diabetes Complications; Female; Heart Diseases; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2013
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC women's health, 2013, Mar-23, Volume: 13 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; United States; Women's Health	2013
[Postmenopausal osteoporosis: Primary prevention or excessive use of medications]. Semergen, 2013, Volume: 39, Issue:3 Topics: Aged; Cross-Sectional Studies; Diphosphonates; Drug Utilization; Female; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Thiophenes	2013
The SERM raloxifene improves diaphyseal fracture healing in mice. Journal of bone and mineral metabolism, 2013, Volume: 31, Issue:6 Topics: Animals; Diaphyses; Estrogens; Female; Femoral Fractures; Femur; Fracture Healing; Fractures, Bone; Humans; Mice; Mice, Inbred C57BL; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2013
[As regards "Post-menopausal osteoporosis: primary prevention or excessive medication"]. Semergen, 2014, Volume: 40, Issue:2 Topics: Diphosphonates; Drug Utilization; Female; Humans; Organometallic Compounds; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Thiophenes	2014
Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Case-Control Studies; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Humans; Incidence; Medication Adherence; Middle Aged; National Health Programs; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Secondary Prevention; Taiwan	2013
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1 Topics: Aged; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Europe; Female; Health Care Costs; Health Services Research; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Sensitivity and Specificity	2014
Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:1 Topics: Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Stroke	2014
In reply. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:1 Topics: Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Stroke	2014
Individualizing osteoporosis medications. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:3 Topics: Absorptiometry, Photon; Administration, Intranasal; Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Female; Hip Fractures; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Precision Medicine; Raloxifene Hydrochloride; Risk Factors; Vitamin D	2014
Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug delivery, 2015, Volume: 22, Issue:6 Topics: Administration, Intranasal; Administration, Oral; Animals; Area Under Curve; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Liberation; Drug Stability; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Nanoparticles; Osteoporosis, Postmenopausal; Particle Size; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators	2015
Osteoporosis knowledge in patients with a first fragility fracture in Puerto Rico. Boletin de la Asociacion Medica de Puerto Rico, 2014, Volume: 106, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Comorbidity; Cross-Sectional Studies; Diphosphonates; Educational Status; Female; Fractures, Spontaneous; Health Literacy; Humans; Income; Insurance Coverage; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patients; Puerto Rico; Raloxifene Hydrochloride; Risk Factors; Surveys and Questionnaires; Vitamin D	2014
Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis. Archives of osteoporosis, 2014, Volume: 9 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control Studies; Female; Humans; Kuwait; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride	2014
Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study. Current medical research and opinion, 2015, Volume: 31, Issue:1 Topics: Aged; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Female; Humans; Japan; Middle Aged; Osteoporosis, Postmenopausal; Pain; Pain Measurement; Product Surveillance, Postmarketing; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires	2015
Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis. Health and quality of life outcomes, 2014, Dec-12, Volume: 12 Topics: Activities of Daily Living; Aged; Bone Density Conservation Agents; Female; Health Surveys; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain; Pain Measurement; Patient Outcome Assessment; Prospective Studies; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires; Treatment Outcome	2014
Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis. Clinical and experimental nephrology, 2015, Volume: 19, Issue:5 Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Female; Humans; Isoenzymes; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis; Tartrate-Resistant Acid Phosphatase	2015
Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:10 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Japan; Osteoporosis, Postmenopausal; Postmenopause; Product Surveillance, Postmarketing; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires; Treatment Outcome	2015
Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database. PloS one, 2015, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Administration Schedule; Drug Prescriptions; Female; Humans; Insurance, Health; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Seoul	2015
Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis. BMC musculoskeletal disorders, 2015, Aug-19, Volume: 16 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Middle Aged; Mortality; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Spinal Fractures; Vertebroplasty	2015
[Selective estrogen receptor modulators (SERMs)]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:10 Topics: Bone Density; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2015
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Archives of osteoporosis, 2017, Volume: 12, Issue:1 Topics: Aged; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Logistic Models; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; United States; Zoledronic Acid	2017
[Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)]. Vnitrni lekarstvi, 2008, Volume: 54, Issue:3 Topics: Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Surveys and Questionnaires	2008
The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Animals; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Evidence-Based Medicine; Female; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2009
Are the serum levels of sCD40L modified by raloxifene in postmenopausal women? European journal of obstetrics, gynecology, and reproductive biology, 2008, Volume: 140, Issue:2 Topics: CD40 Ligand; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women. Archives of gynecology and obstetrics, 2009, Volume: 279, Issue:4 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sexual Behavior; Surveys and Questionnaires	2009
Understanding risk factors, screening, and treatment of postmenopausal osteoporosis. Orthopedics, 2008, Volume: 31, Issue:7 Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide	2008
Raloxifene-induced acceleration of platelet aggregation. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:17 Topics: Blood Platelets; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorylation; Platelet Aggregation; Raloxifene Hydrochloride; Signal Transduction; Thrombosis	2008
[Treatment of osteoporosis in the elderly: what is the evidence?]. Tijdschrift voor gerontologie en geriatrie, 2008, Volume: 39, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome	2008
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC women's health, 2008, Dec-23, Volume: 8 Topics: Aged; Bone Density Conservation Agents; Chi-Square Distribution; Diphosphonates; Female; Humans; Insurance Claim Reporting; Logistic Models; Medicaid; Medicare; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal; Patient Selection; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome; United States	2008
Raloxifene enhances spontaneous microaggregation of platelets through upregulation of p44/p42 MAP kinase: a case report. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:1 Topics: Blood Platelets; Bone Density Conservation Agents; Cells, Cultured; Female; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteoporosis, Postmenopausal; Platelet Aggregation; Raloxifene Hydrochloride; Up-Regulation	2010
Effects of UGT1A128 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. British journal of clinical pharmacology, 2009, Volume: 67, Issue:4* Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Female; Glucuronosyltransferase; Humans; Middle Aged; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Raloxifene Hydrochloride; Tandem Mass Spectrometry; Treatment Outcome; Young Adult	2009
A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system. Acta biochimica Polonica, 2009, Volume: 56, Issue:2 Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow Cells; Bone Resorption; Calcification, Physiologic; Calcium; Cell Count; Cells, Cultured; Disease Models, Animal; Drug Combinations; Estradiol; Estriol; Female; Gene Expression; Genistein; Humans; Mice; Mice, Inbred BALB C; Organ Size; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Ovariectomy; Phytoestrogens; Raloxifene Hydrochloride; Rats; Rats, Wistar; RNA, Messenger; Selective Estrogen Receptor Modulators; Thymus Gland; Uterus	2009
Raloxifene and risk for stroke based on the framingham stroke risk score. The American journal of medicine, 2009, Volume: 122, Issue:8 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Stroke	2009
Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats. European journal of obstetrics, gynecology, and reproductive biology, 2009, Volume: 147, Issue:2 Topics: Animals; Bone Density; Bone Density Conservation Agents; Female; Humans; Misoprostol; Organometallic Compounds; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes	2009
Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2010, Volume: 19, Issue:1 Topics: Aged; Bone Density Conservation Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2010
Lasofoxifene: new drug. Osteoporosis: no better than raloxifene. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Europe; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes	2009
Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. Geriatrics & gerontology international, 2010, Volume: 10, Issue:1 Topics: Aged; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Female; Humans; Hypertension; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Renin-Angiotensin System; Selective Estrogen Receptor Modulators	2010
FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis. American family physician, 2010, Feb-15, Volume: 81, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride	2010
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
[Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Female; Humans; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Time Factors	2010
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcified tissue international, 2010, Volume: 86, Issue:5 Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Studies; Comorbidity; Confounding Factors, Epidemiologic; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Pulmonary Disease, Chronic Obstructive; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors	2010
Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study. Scandinavian journal of public health, 2010, Volume: 38, Issue:5 Topics: Adult; Aged; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Educational Status; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Education as Topic; Raloxifene Hydrochloride; Surveys and Questionnaires	2010
Two good choices to prevent breast cancer: great taste, less filling. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus	2010
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Female; Frail Elderly; Hip Fractures; Humans; Humerus; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Pennsylvania; Radius Fractures; Raloxifene Hydrochloride; Ulna Fractures	2011
Fracture risk in early postmenopausal women assessed using FRAX. Joint bone spine, 2010, Volume: 77, Issue:4 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Hip Fractures; Humans; Middle Aged; Models, Statistical; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors	2010
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone, 2010, Volume: 47, Issue:5 Topics: Aged; Algorithms; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2010
Evista patents upheld. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:10 Topics: Animals; Drug Industry; Humans; Osteoporosis, Postmenopausal; Patents as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2010
Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:2 Topics: Aged; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies	2011
Raloxifene temporarily reduces arterial stiffness. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:6 Topics: Aged; Ankle Brachial Index; Arteries; Atherosclerosis; Bone Diseases, Metabolic; Case-Control Studies; Elasticity; Female; Humans; Linear Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2010
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. European journal of pharmacology, 2011, Jan-15, Volume: 650, Issue:2-3 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Estradiol; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Messenger	2011
Tipping the balance for the primary prevention of breast cancer. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2010
Third-generation SERMs may face uphill battle. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2010
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:1 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes	2011
Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87 Suppl 3 Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide; Therapies, Investigational; Treatment Outcome	2004
Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis. Clinical and experimental immunology, 2011, Volume: 165, Issue:1 Topics: Animals; Antibodies; Arthritis, Experimental; Biomarkers; Bone Marrow; Collagen; Disease Progression; Estradiol; Female; Humans; Immunomodulation; Mice; Mice, Inbred DBA; Mice, Transgenic; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Response Elements; Selective Estrogen Receptor Modulators; Transgenes	2011
Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15 Suppl 1 Topics: Absorptiometry, Photon; Aged; Asian People; Bone Density; Bone Density Conservation Agents; Calcium; Case-Control Studies; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis; Severity of Illness Index; Time Factors	2011
Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Diphosphonates; Drug Administration Schedule; Female; Genetic Markers; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators	2012
Osteoporosis screening and treatment guidelines: are they being followed? Menopause (New York, N.Y.), 2011, Volume: 18, Issue:10 Topics: Absorptiometry, Photon; Aged; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Cohort Studies; Diphosphonates; Exercise Therapy; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Vitamin D	2011
Effect of Cissus quadrangularis Linn on the development of osteopenia induced by ovariectomy in rats. La Clinica terapeutica, 2011, Volume: 162, Issue:4 Topics: Acid Phosphatase; Alkaline Phosphatase; Alkanes; Animals; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cissus; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Femur; Humans; Hydroxyproline; Isoenzymes; Osteoporosis, Postmenopausal; Ovariectomy; Phytotherapy; Plant Extracts; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase	2011
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Female; General Practice; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Thiophenes; Time Factors; United Kingdom	2012
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels. Journal of endocrinological investigation, 2012, Volume: 35, Issue:7 Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Glucocorticoids; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Severity of Illness Index; Vitamin K Deficiency	2012
Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:2 Topics: Adiponectin; Aged; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Female; Humans; Leptin; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2012
MENOPOST--calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:2 Topics: Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D	2013
Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:6 Topics: Aged; Asian People; Bone Density; Collagen Type I; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Product Surveillance, Postmarketing; Raloxifene Hydrochloride	2012
Hypocalcemia induced by raloxifene. Current drug safety, 2012, Volume: 7, Issue:2 Topics: Aged, 80 and over; Bone Density Conservation Agents; Female; Humans; Hypocalcemia; Mass Screening; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Vitamin D Deficiency	2012
Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene. Journal of orthopaedic surgery (Hong Kong), 2012, Volume: 20, Issue:2 Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Female; Femur; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride	2012
Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:12 Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide	2012
Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study. Current medical research and opinion, 2012, Volume: 28, Issue:11 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Japan; Middle Aged; Osteoporosis, Postmenopausal; Product Surveillance, Postmarketing; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome	2012
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:4 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Incidence; Indoles; Models, Economic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome	2013
[Current therapeutic means]. Presse medicale (Paris, France : 1983), 2002, Apr-20, Volume: 31, Issue:15 Topics: Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results	2002
Improvement in the undertreatment of osteoporosis following hip fracture. The Journal of bone and joint surgery. American volume, 2002, Volume: 84, Issue:8 Topics: Aged; Aged, 80 and over; Calcitonin; Calcium; Female; Femoral Neck Fractures; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; United States	2002
[What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist]. Ceska gynekologie, 2002, Volume: 67, Issue:4 Topics: Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
[Osteoporosis: diagnosis, prevention and treatment]. Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:2 Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators	2002
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures	2002
Medications for postmenopausal osteoporosis prevention. Harvard women's health watch, 2002, Volume: 10, Issue:4 Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators	2002
ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999). International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2002, Volume: 79, Issue:3 Topics: Adult; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2002
[Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis]. Minerva medica, 2002, Volume: 93, Issue:6 Topics: Analysis of Variance; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Sodium Fluoride	2002
Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Human reproduction (Oxford, England), 2003, Volume: 18, Issue:1 Topics: Aged; Amino Acids; Bone Density; Double-Blind Method; Female; Genotype; Heterozygote; Homozygote; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators	2003
[Absolutely not true and relatively true about risk reduction]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Jan-09, Volume: 123, Issue:1 Topics: Advertising; Drug Information Services; Estrogen Antagonists; Female; Fractures, Spontaneous; Humans; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Venous Thrombosis	2003
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2003
Osteoporosis guidelines. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Jun-24, Volume: 168, Issue:13 Topics: Canada; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Osteoporosis guidelines. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Jun-24, Volume: 168, Issue:13 Topics: Aged; Canada; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Venous Thrombosis	2003
[SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half]. MMW Fortschritte der Medizin, 2003, May-29, Volume: 145, Issue:22 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Incidence; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
[Osteoporosis therapy compared. More solid bones with bisphosphonates]. MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32 Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front]. MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28 Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors	2003
[Therapy of postmenopausal osteoporosis]. Der Orthopade, 2003, Volume: 32, Issue:12 Topics: Activities of Daily Living; Aged; Calcitonin; Calcium; Diphosphonates; Estrogen Antagonists; Estrogens; Exercise; Female; Fluorides; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Progestins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D; Walking	2003
Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women. Report on medical guidelines & outcomes research, 2004, Mar-05, Volume: 15, Issue:5 Topics: Dose-Response Relationship, Drug; Female; Hormone Replacement Therapy; Hot Flashes; Humans; Hyperhidrosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Urinary Incontinence; Vasomotor System	2004
Osteoporosis--diagnosis, treatment and management. Australian family physician, 2004, Volume: 33, Issue:3 Topics: Aged; Calcitriol; Diphosphonates; Disease Progression; Evidence-Based Medicine; Female; Humans; Life Style; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors	2004
[Evidence-based medicine and drug selection of osleoporosis prevention after menopause]. Zhonghua yi xue za zhi, 2004, Feb-17, Volume: 84, Issue:4 Topics: China; Drug Evaluation, Preclinical; Estrogen Antagonists; Estrogens; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2004
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach]. Praxis, 2004, Mar-10, Volume: 93, Issue:11 Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Vitamin D	2004
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:5 Topics: Acid Phosphatase; Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Collagen Type I; Data Interpretation, Statistical; Female; Fractures, Bone; Humans; Long-Term Care; Nursing Homes; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vitamin D	2004
Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:5 Topics: Adverse Drug Reaction Reporting Systems; Aged; Drug Interactions; England; Family Practice; Female; Flushing; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2005
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology, 2004, Aug-24, Volume: 63, Issue:4 Topics: Age Factors; Aged; Blood Glucose; Brain; Cardiovascular Diseases; Cognition Disorders; Comorbidity; Dementia; Depression; Diabetes Mellitus; Fasting; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Middle Aged; Obesity; Odds Ratio; Osteoporosis, Postmenopausal; Prediabetic State; Psychological Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Tomography, X-Ray Computed	2004
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:9 Topics: Age Distribution; Aged; Bone Density; Breast Neoplasms; Calcium; Cardiovascular Diseases; Female; Global Health; Hip Fractures; Humans; Incidence; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Selection; Population Surveillance; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D	2004
[Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide	2004
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Health-economic comparison of three recommended drugs for the treatment of osteoporosis. International journal of clinical pharmacology research, 2004, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2004
CORE breast-cancer prevention trial. The Lancet. Oncology, 2005, Volume: 6, Issue:1 Topics: Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2005
Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute, 2005, Apr-06, Volume: 97, Issue:7 Topics: Breast Neoplasms; Confounding Factors, Epidemiologic; Cyclooxygenase 2; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Female; Humans; Incidence; Membrane Proteins; Osteoporosis, Postmenopausal; Prostaglandin-Endoperoxide Synthases; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thromboembolism; Treatment Outcome; United States	2005
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstetrics and gynecology, 2005, Volume: 105, Issue:5 Pt 2 Topics: Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Osteoporosis, Postmenopausal; Ovariectomy; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	2005
Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene. Maturitas, 2005, Jun-16, Volume: 51, Issue:2 Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Endometrium; Female; Humans; Osteoporosis, Postmenopausal; Polyps; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Diseases; Uterine Hemorrhage	2005
Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women. Danish medical bulletin, 2005, Volume: 52, Issue:2 Topics: Animals; Atherosclerosis; Bone and Bones; Cardiovascular System; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:2 Topics: Adipose Tissue; Aged; Aged, 80 and over; Biomarkers; Body Fat Distribution; Bone Density Conservation Agents; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Japan; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Antiresorptive agents, raloxifene, and PHARMAC. The New Zealand medical journal, 2006, Mar-10, Volume: 119, Issue:1230 Topics: Aged; Bone Density Conservation Agents; Drug Approval; Drug Evaluation; Female; Fractures, Spontaneous; Humans; New Zealand; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Treatment Outcome	2006
Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients? European journal of gynaecological oncology, 2006, Volume: 27, Issue:2 Topics: Adult; Bone Density Conservation Agents; Breast; Estrogen Receptor Modulators; Female; Humans; Mammography; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies	2006
[New therapeutic approaches to osteoporosis]. Annales d'endocrinologie, 2006, Volume: 67, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride	2006
Model-based drug development: the road to quantitative pharmacology. Journal of pharmacokinetics and pharmacodynamics, 2006, Volume: 33, Issue:3 Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Biomarkers; Clinical Trials as Topic; Computer Simulation; Decision Making; Deoxycytidine; Dose-Response Relationship, Drug; Drug Industry; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Biological; Osteocalcin; Osteoporosis, Postmenopausal; Pharmacology; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2006
[The successful development of bisphosphonates in the therapy of osteoporosis]. Medizinische Klinik (Munich, Germany : 1983), 2006, Volume: 101 Suppl 1 Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Risk Reduction Behavior	2006
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Current medical research and opinion, 2006, Volume: 22, Issue:7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Etidronic Acid; Female; Humans; Markov Chains; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2006
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. Journal of bone and mineral metabolism, 2006, Volume: 24, Issue:5 Topics: Aged; Asian People; Bone Density Conservation Agents; China; Female; Fractures, Bone; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-01, Volume: 12, Issue:17 Topics: Aged; Breast Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2006
Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:5 Topics: Absorptiometry, Photon; Aged; Body Mass Index; Bone Density; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Time Factors	2006
[Osteoporosis priority: Reduce the number of fractures]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Bone; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Teriparatide; Thiophenes; Time Factors	2006
Why is the RUTH trial so important? Maturitas, 2007, Feb-20, Volume: 56, Issue:2 Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Coronary Artery Disease; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2007
Raloxifene vs tamoxifen. JAMA, 2007, Jan-17, Volume: 297, Issue:3 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Current medical research and opinion, 2006, Volume: 22, Issue:12 Topics: Aged; Analgesics; Arthralgia; Back Pain; Bone Density; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Sleep	2006
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Back Pain; Estrogens; Fatigue; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Tamoxifen; United States	2007
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. The American journal of medicine, 2007, Volume: 120, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States	2007
QUS in monitoring raloxifene and estrogen-progestogens: a 4-year longitudinal study. Ultrasound in medicine & biology, 2007, Volume: 33, Issue:8 Topics: Aged; Bone Density; Bone Density Conservation Agents; Drug Monitoring; Estrogen Replacement Therapy; Female; Finger Phalanges; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography	2007
Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:9 Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Glucose Intolerance; Humans; Insulin Resistance; Liver; Liver Cirrhosis; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index	2007
The long-term effect of raloxifene on the genitourinary tract. Climacteric : the journal of the International Menopause Society, 2007, Volume: 10, Issue:3 Topics: Aged; Aged, 80 and over; Case-Control Studies; Drug Administration Schedule; Female; Humans; Italy; Middle Aged; Osteoporosis, Postmenopausal; Prevalence; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Surveys and Questionnaires; Urinary Incontinence, Stress; Uterine Prolapse	2007
Osteoporosis: non-hormonal treatment. Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health	2007
Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis and rheumatism, 2007, Volume: 56, Issue:10 Topics: Animals; Arthritis; Arthritis, Experimental; Bone Density; Cytokines; Female; Humans; Mice; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Thiophenes; Treatment Outcome; Tumor Necrosis Factor-alpha	2007
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:6 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride	2008
[Long term effects of raloxifen on the bones]. Ugeskrift for laeger, 2008, Jan-21, Volume: 170, Issue:4 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Time Factors; Treatment Outcome	2008
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:8 Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure	2008
Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:7 Topics: Aged; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Prescriptions; Female; France; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Practice Patterns, Physicians'; Raloxifene Hydrochloride	2008
Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clinical and experimental immunology, 2008, Volume: 152, Issue:3 Topics: Animals; Arthritis, Experimental; Biomarkers; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Interleukin-6; Mice; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Treatment Outcome	2008
Summaries for patients. Drug therapy for osteoporosis. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:5 Topics: Absorptiometry, Photon; Animals; Bone Density; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Femur; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reproducibility of Results	1994
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone, 1996, Volume: 18, Issue:6 Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus	1996
Estrogen and bone: new pieces to the puzzle. Nature medicine, 1996, Volume: 2, Issue:10 Topics: Animals; Bone Resorption; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Mice; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor beta	1996
Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Jan-15, Volume: 55, Issue:2 Topics: Adult; Aged; Bone Density; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
New drug approved to help prevent osteoporosis. Mayo Clinic health letter (English ed.), 1998, Volume: 16, Issue:3 Topics: Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
Raloxifene for postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 1998, Mar-13, Volume: 40, Issue:1022 Topics: Bone Density; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Thromboembolism	1998
Effects of raloxifene in postmenopausal women. The New England journal of medicine, 1998, Apr-30, Volume: 338, Issue:18 Topics: Bone Density; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Research Design	1998
Effects of raloxifene in postmenopausal women. The New England journal of medicine, 1998, Apr-30, Volume: 338, Issue:18 Topics: Affect; Estrogen Antagonists; Female; Humans; Memory; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
Anti-estrogens come of age: a pioneer looks back. Journal of the National Cancer Institute, 1998, May-06, Volume: 90, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	1998
A new alternative to estrogen: raloxifene. Health news (Waltham, Mass.), 1998, Jun-25, Volume: 4, Issue:8 Topics: Bone Density; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
[Current trends in prevention and therapy of postmenopausal osteoporosis]. Recenti progressi in medicina, 1998, Volume: 89, Issue:6 Topics: Animals; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Rats; Time Factors	1998
Biological basis of anti-resorptive therapies for osteoporosis. Aging (Milan, Italy), 1998, Volume: 10, Issue:2 Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
Clinical efficacy of SERMs. Aging (Milan, Italy), 1998, Volume: 10, Issue:2 Topics: Aged; Bone Density; Estrogen Antagonists; Estrogens; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen	1998
Role of novel antiresorptive agents for the prevention and treatment of osteoporosis. European journal of endocrinology, 1998, Volume: 139, Issue:1 Topics: Alendronate; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
Designer estrogens. Scientific American, 1998, Volume: 279, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen	1998
Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis. The Nurse practitioner, 1998, Volume: 23, Issue:9 Topics: Adult; Aged; Bone Density; Drug Interactions; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a Harvard women's health watch, 1998, Volume: 6, Issue:3 Topics: Alendronate; Colonic Diseases, Functional; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1998
Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women. American journal of obstetrics and gynecology, 1998, Volume: 179, Issue:6 Pt 1 Topics: Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	1998
Tamoxifen for prevention of breast cancer. The Medical letter on drugs and therapeutics, 1999, Jan-01, Volume: 41, Issue:1043 Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis	1999
[Raloxifene]. Deutsche medizinische Wochenschrift (1946), 1999, Jan-08, Volume: 124, Issue:1-2 Topics: Adult; Contraindications; Controlled Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Pregnancy; Raloxifene Hydrochloride	1999
[Bone and hormones. Estrogens and antiestrogens: action on osteoporosis]. Presse medicale (Paris, France : 1983), 1999, Mar-13, Volume: 28, Issue:10 Topics: Aged; Clinical Trials, Phase III as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipids; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Tamoxifen; Time Factors	1999
Using SERMS for treating postmenopausal symptoms. Community nurse, 1999, Volume: 4, Issue:12 Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	1999
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Archives of internal medicine, 1999, Jul-12, Volume: 159, Issue:13 Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity	1999
Osteoporosis: protecting bone mass with fundamentals and drug therapy. Geriatrics, 1999, Volume: 54, Issue:7 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietary Supplements; Estrogen Replacement Therapy; Estrogens; Exercise; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Risk Factors; Smoking Cessation; Vitamin D	1999
Raloxifene reduces spinal fractures postmenopausally. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Aged; Aged, 80 and over; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Spinal Fractures	1999
Designer estrogens: breast cancer benefit, remaining questions. Health news (Waltham, Mass.), 1999, Jul-25, Volume: 5, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1999
Therapy for fracture prevention. JAMA, 1999, Aug-18, Volume: 282, Issue:7 Topics: Bone Density; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk	1999
Sex steroid analogs. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1999, Volume: 9 Suppl 2 Topics: Animals; Bone Resorption; Breast Neoplasms; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Hormones; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen	1999
SERM: a new concept in the management of osteoporosis. Presentation. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Fewer fractures with raloxifene. Health news (Waltham, Mass.), 1999, Oct-01, Volume: 5, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
Biochemical bone markers. CAP today, 1999, Volume: 13, Issue:5 Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Lipids; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride	1999
Frequency of bone densitometry for osteoporosis? Postgraduate medicine, 1999, Volume: 106, Issue:6 Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors	1999
Raloxifene. Southern medical journal, 1999, Volume: 92, Issue:11 Topics: Bone Density; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterus	1999
[Selective estrogen receptor modulators (SERM's) in postmenopausal women]. Nederlands tijdschrift voor geneeskunde, 1999, Nov-27, Volume: 143, Issue:48 Topics: Aged; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	1999
Report examines strategies for reducing breast cancer risk. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jul-01, Volume: 56, Issue:13 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk	1999
Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas, 2000, Jan-15, Volume: 34, Issue:1 Topics: Adult; Double-Blind Method; Estrogen Antagonists; Female; Hot Flashes; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Time Factors	2000
New ways to manage the old problem of osteoporosis. JAAPA : official journal of the American Academy of Physician Assistants, 1999, Volume: 12, Issue:9 Topics: Aged; Alendronate; Bone Density; Diagnosis, Differential; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	1999
Raloxifene therapy in the reduction of fractures. American family physician, 2000, Mar-01, Volume: 61, Issue:5 Topics: Aged; Blood Coagulation Factors; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Incidence; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
[Raloxifene (Celvista, Evista)]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:1 Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage	2000
Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:3 Topics: Androgens; Animals; B-Lymphocytes; Bone Marrow; Bone Remodeling; Bone Resorption; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hematopoiesis; Humans; Lymphocyte Count; Male; Mice; Orchiectomy; Organ Size; Osteoporosis; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Uterus	2000
Raloxifene and risk of vertebral fracture in postmenopausal women. JAMA, 2000, May-03, Volume: 283, Issue:17 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2000
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone, 2000, Volume: 27, Issue:1 Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk	2000
Bone structure in patients with low bone mineral density with or without vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:7 Topics: Age Factors; Aged; Bone and Bones; Bone Density; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Raloxifene Hydrochloride; Regression Analysis; Spinal Fractures	2000
Reduction of vertebral fracture risk with raloxifene. The Journal of family practice, 1999, Volume: 48, Issue:11 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
New drugs, new effects, new problems. The American journal of nursing, 2000, Volume: 100, Issue:8 Topics: Atrophy; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Medication Errors; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Vaginitis	2000
Raloxifene therapy. Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:9 Topics: Accidental Falls; Central Nervous System; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Alendronic acid in primary prevention: new indication. No reduction in fracture risk. Prescrire international, 2000, Volume: 9, Issue:47 Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
Drugs for prevention and treatment of postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D	2000
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? Bone, 2000, Volume: 27, Issue:6 Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2000
Drug information needs clarification. Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results; Risk Factors	2001
[SERM-therapy in postmenopause. Protection of bone and breast]. MMW Fortschritte der Medizin, 2001, Jan-25, Volume: 143, Issue:4 Topics: Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Treatment Outcome	2001
Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2001,Spring, Volume: 4, Issue:1 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Data Interpretation, Statistical; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Effect of physicians opinion on patients' choice of treatment. European journal of obstetrics, gynecology, and reproductive biology, 2001, Volume: 96, Issue:2 Topics: Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Satisfaction; Physician's Role; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2001
Medication update. Southern medical journal, 2001, Volume: 94, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Dosage Forms; Drug Interactions; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2001
Initiation of osteoporosis treatment after bone mineral density testing. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:5 Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Cohort Studies; Decision Making; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Glucocorticoids; Health Care Rationing; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2001
Rheumatology: 15. Osteoporosis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Jul-10, Volume: 165, Issue:1 Topics: Bone Density; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Life Style; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thoracic Vertebrae; Vitamin D	2001
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated. Prescrire international, 2000, Volume: 9, Issue:50 Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms	2000
Bone builders: preventing and treating osteoporosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:10 Topics: Aged; Estrogen Replacement Therapy; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride	2001
Bone builders: the discoveries behind preventing and treating osteoporosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:10 Topics: Aged; Calcium; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride	2001
Raloxifene: new preparation. Not better than oestrogen. Prescrire international, 1999, Volume: 8, Issue:44 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	1999
Design and methods of the Raloxifene Use for The Heart (RUTH) study. The American journal of cardiology, 2001, Aug-15, Volume: 88, Issue:4 Topics: Angina, Unstable; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Selective Estrogen Receptor Modulators	2001
The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis and rheumatism, 2001, Volume: 44, Issue:11 Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Radiography; Raloxifene Hydrochloride; Severity of Illness Index; Sickness Impact Profile; Spinal Fractures	2001
Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis? Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Adult; Aged; Aged, 80 and over; Family Practice; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2001
The role of serial bone mineral density testing for osteoporosis. Journal of women's health & gender-based medicine, 2001, Volume: 10, Issue:9 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Hormone Replacement Therapy; Humans; Osteoporosis, Postmenopausal; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2001
Spontaneous reports of pulmonary embolism in association with raloxifene. Obstetrics and gynecology, 2001, Volume: 98, Issue:6 Topics: Adverse Drug Reaction Reporting Systems; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2001
Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:1 Topics: Aged; Bone Density; Bone Remodeling; Female; Humans; Middle Aged; Models, Biological; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
[Risk-adapted therapy of osteoporosis. Preventing fractures]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Absorptiometry, Photon; Aged; Calcium, Dietary; Cholecalciferol; Diphosphonates; Exercise; Female; Fluorides; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment	2001
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2001
[What do we think about selective estrogen receptor modulators?]. La Revue de medecine interne, 2001, Volume: 22, Issue:12 Topics: Age Factors; Breast Neoplasms; Clinical Trials as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors	2001
Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture. Annals of the New York Academy of Sciences, 2001, Volume: 952 Topics: Amino Acid Substitution; Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Tumor Cells, Cultured	2001
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors	2002
A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA, 2002, Apr-24, Volume: 287, Issue:16 Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2002
Raloxifene remains an option. Canadian family physician Medecin de famille canadien, 2002, Volume: 48 Topics: Aged; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
[Rational and cost effective osteoporosis prevention and therapy]. Der Internist, 2002, Volume: 43, Issue:4 Topics: Aged; Cost-Benefit Analysis; Diphosphonates; Female; Fluorides; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2002